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Abstract: 
The skeletal muscle microcirculation is a key regulator of local blood distribution, 
vascular resistance and overall blood pressure (BP). Arterioles and capillaries are two 
important components of the microcirculation, which can undergo remodeling such as 
arteriogenesis, angiogenesis, or capillary rarefaction. Vascular remodeling requires the 
coordinated action of several factors within the microenvironment. These include: matrix 
metalloproteinases (MMPs) and their endogenous inhibitors, tissue inhibitor of 
metalloproteinases (TIMPs), vascular endothelial growth factor-A (VEGF-A) and 
thrombospondin-1 (TSP-1). The objective of this dissertation was to examine how 
alterations to the microenvironment impacted the ‘appropriate’ microvascular remodeling 
responses to alterations in flow. The skeletal muscle microenvironment was altered 
through manipulation of TIMP1 expression or glucocorticoid (GC) levels. Furthermore, 
blood flow was altered via femoral artery (FA) ligation or prazosin treatment. This 
dissertation includes three primary hypotheses and corresponding findings to examine the 
importance of alterations to the microenvironment on microvascular remodeling. Firstly, 
the loss of TIMP1 would enhance both ischemia and flow-induced vascular remodeling 
by increasing MMP activity. Using TIMP1 deficient mice (Timp1-/-), we demonstrated 
that TIMP1 is integral for vascular network maturation. Additionally, TIMP1 is required 
for microvascular adaptations to alterations in flow. This was proven by the absence of 
arteriogenesis and/or angiogenesis in Timp1-/- mice in response to elevations in flow 
despite an increase in both VEGF-A and eNOS mRNA. Secondly, Corticosterone 
(CORT) treatment would inhibit endothelial mediated shear stress signaling and 
subsequently, the microvascular remodeling responses to prazosin administration. Lastly, 
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CORT mediated hypertension and microcirculatory rarefaction would be prevented with 
2 weeks of concurrent prazosin or Tempol (a ROS scavenger) administration. Endothelial 
cell responsiveness to shear stress was partially blunted by CORT pre-treatment. The lack 
of vascular remodeling (angiogenesis and arteriogenesis) and prevention of GC-mediated 
capillary rarefaction in CORT-prazosin animals supports this finding. The maintenance 
of vascular tone and skeletal muscle blood flow, more so then lowering circulating levels 
of ROS, was responsible for mitigating CORT-induced capillary rarefaction and 
hypertension. Taken together, these three studies demonstrate that perturbations of the 
microenvironment, due to the loss of TIMP1 or elevated GCs, results in impaired 
microvascular remodeling to alterations in flow.  Furthermore, alterations to the skeletal 
muscle microcirculation can impact overall cardiovascular health. 
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Chapter 1: Literature Review 
1.0: The cardiovascular system: 
The mammalian cardiovascular (CV) system is a closed loop system comprised of 
a heart and blood vessels. CV health is integral for overall quality of life, health and 
longevity. The prevalence of CV disease is on the rise in Canada (Lovell et al., 2009); 
therefore understanding CV regulatory mechanisms is imperative for improvements to be 
made and vascular health to be maintained.  
1.1 The vascular tree  
The mammalian arterial system is a highly organized vascular system that ensures 
that all cells are within 100 to 200µm of oxygen and nutrients. This system is comprised 
of larger arteries, which subsequently branch into smaller arteries and smaller arterioles 
until reaching the smallest vessels, the capillaries. De-oxygenated nutrient poor blood 
will empty from the capillaries into venules as the venous system functions primarily to 
return blood back to the heart.  
Each component of the arterial tree has distinct and important functions. For 
example, large peripheral arteries are responsible for transporting oxygenated blood away 
from the heart and towards organs/tissues. These vessels have a large diameter, thus 
blood is rapidly transported as it encounters very little resistance. Of interest in the 
current review are the structure, function and adaptability of the microcirculation.  
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1.1.1 The microcirculation 
The microcirculation is defined as the segment of the circulation comprising small 
arteries, arterioles, capillaries and venules. The venule component of the microcirculation 
will not be discussed further. From here forward the term microcirculation will be used to 
describe arteries, arterioles and capillaries 150µm or smaller in diameter (Figure 1.1A). 
The microcirculation is the largest paracrine organ in the body, a key regulator of 
vascular homeostasis and an important contributor to disease pathology (Gutterman et al., 
2016). In fact, alterations in microcirculatory function precedes overt signs of CV disease 
(Gutterman et al., 2016).   
An important difference between arterioles and capillaries is that at the arteriolar 
level, one or more layers of smooth muscle cells and connective/elastic tissue (tunica 
media and externa) surround the endothelium, which is absent at the capillary level. 
Capillaries gain structural support from both pericytes and their basement membrane. 
While pericyte coverage is sporadic (Ribatti et al., 2011), they are nonetheless important 
in the maintenance of endothelial cell homeostasis (Gerhardt and Betsholtz, 2003; Haas 
et al., 2012) and play a role in vascular remodeling (Ribatti et al., 2011).   
The endothelial layer of the microcirculation is an important factor in vascular 
and CV health. A key job of the endothelium is to detect and respond to alterations in 
shear stress, the frictional force exerted as blood flows past the endothelial surface, via 
mechanotransduction. Mechanotransduction is defined as the mechanisms through which 
a cell can detect a mechanical stimulus and convert it into chemical activity (Weinbaum 
et al., 2003; Chien, 2007). Within endothelial cells, there are a number of possible 
mechanosensors including: ion channels (Ando and Yamamoto, 2009), protein coupled 
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receptors (Kuchan et al., 1994), caveolae (Rizzo et al., 2003), adhesion proteins (Burridge 
and Chrzanowska-Wodnicka, 1996; Osawa et al., 2002; Tzima et al., 2005), the 
glycocalyx (Tarbell and Pahakis, 2006), primary cilia (Nauli et al., 2008) and tyrosine 
kinase receptors (Wang et al., 2002).  
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Figure 1.1: The  microenvironment of the skeletal muscle microvasculature 
 
A) Schematic representation of the skeletal muscle microcirculation. B) Closer view of the 
microcirculation highlighting the components of the microenvironment from the arteriolar (left 
side) down to the capillary (right side) level. The microenvironment consists of numerous 
components including: skeletal muscle cells/myocytes, smooth muscle cells, endothelial cells, 
pericytes, the ECM, local hemodynamics and circulating factors secreted by cells within 
microenvironment. All of these factors can in turn modulate changes to one or more of the cell 
types shown, thereby impacting vascular homeostasis and remodeling.  
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Once one or more mechanosensors have been activated the resulting signaling 
cascade modulates the expression of a variety of genes and proteins involved in the 
regulation of endothelial cell behavior (Chien, 2007). An alteration in blood flow/shear 
stress is an important stimulus for vascular remodeling. Increased blood flow elicits 
outward arteriolar remodeling (section 1.3.1) and splitting angiogenesis (section 1.3.2.2), 
whereas reduced blood flow elicits inward arterial remodeling and capillary rarefaction 
(1.5.1.1).  
In vitro, endothelial shear stress can be simulated using a parallel plate flow 
chamber, which exposes a monolayer of endothelial cells to a fixed shear stress intensity 
(Ives et al. 1986; Milkiewicz et al. 2006). This protocol allows for the analysis of 
alterations in endothelial cell derived factors in response to elevated shear stress versus 
control cells. In vivo shear stress can be augmented using an α1 adrenergic receptor 
antagonist such as prazosin (for more information see section 1.5.2) (Milkiewicz et al., 
2001).  
The microcirculation has several important roles within skeletal muscle. One 
important function is the modulation of local blood flow distribution. This can be 
accomplished, in part, by alterations in arteriolar diameter.  Diameter can be modulated 
by local metabolites, alterations in blood flow, temperature as well as through changes in 
the relative expression of vasodilatory or constriction factors (Sherwood and Kell, 2010). 
Additionally, capillaries play an important role in blood flow distribution due primarily to 
their orientation and proximity to cells. Within skeletal muscle, capillaries are oriented 
along the length of a muscle fiber and all cells are within 0.01cm of a capillary. These 
features enable easy diffusion, from the capillary to underlying tissue, thereby providing 
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the local microenvironment with access to oxygen and nutrients (Potter and Groom, 
1983).  
Another important function of the microcirculation is as a regulator of vascular 
resistance and blood pressure. This is due in part to the small size and large proportion of 
arterioles; the body contains over half a million arterioles. These features enable 
arterioles to offer a large amount of blood flow resistance (Mulvany and Aalkjaer, 1990; 
Gutterman et al., 2016). As well, the capillary network impacts vascular resistance, as 
seen by the finding that reductions in capillary number increases peripheral resistance and 
blood pressure (Greene et al., 1989; Humar et al., 2009). Additionally the 
microcirculation functions as a regulator of metabolic status. This was recently 
demonstrated by the finding that greater skeletal muscle capillary content corresponds 
with improved insulin sensitivity and glucose clearance (Akerstrom et al., 2014).  
1.2 The cellular microenvironment  
The cellular microenvironment is defined as factors that can affect the conditions 
surrounding a cell or group of cells thus altering their behavior, structure and/or function 
(Barthes et al., 2014). This encompasses the basement membrane, extracellular matrix 
(ECM), surrounding cells, cytokines, hormones or other bioactive agents and mechanical 
forces such as blood flow (Barthes et al., 2014). The current review is focused on the 
microenvironment of the skeletal muscle microcirculation, which is comprised of 
endothelial cells, basement membrane, ECM, pericytes, smooth muscle cells, skeletal 
muscle fibers, satellite cells, and factors secreted from all of the above mentioned cell 
types (Figure 1.1B). Additionally, trans-membrane proteins such as integrins are 
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important factors that aid in communication within the microenvironment (Chen et al., 
1999).  
 The basement membrane is an important component of the microenvironment; the 
basement membrane is primarily comprised of type IV collagen and laminin. The 
basement membrane contains pro and anti-remodeling factors such as vascular 
endothelial growth factor (VEGF) and thrombospondin-1 (TSP-1) as well as pericytes at 
the capillary level (Hansen-Smith et al., 1996). Cellular survival is largely dependent on 
cell adhesion to the basement membrane. However, appropriate degradation and 
remodeling of the basement membrane and ECM occurs during vascular remodeling 
(Tronc et al., 2000; Pepper, 2001; Kuzuya and Iguchi, 2003; Haas, 2005; Haas et al., 
2007) (see section 1.4.3).  
The different cell types within the microenvironment must communicate with one 
another to ensure a normal and healthy microvasculature. For example, endothelial cells 
communicate with smooth muscle cells to help maintain vascular smooth muscle cells in 
a differentiated/contractile phenotype, a requisite for a mature, healthy and functional 
artery or arteriole (Powell et al., 1996; Powell et al., 1997). Furthermore, communication 
between skeletal myocytes and endothelial cells is important for microvascular 
homeostasis and remodeling, likely due to the cross talk with factors such as VEGF and 
nitric oxide (NO) (Uchida et al., 2015).  
  
 8!
1.3: Microvascular Remodeling  
Alterations to the microenvironment will profoundly impact the microvasculature, 
which is not a static structure and has the ability to adapt over time. There are three kinds 
of vascular remodeling; vasculogenesis, angiogenesis and arteriogenesis. Vasculogenesis 
is the embryonic development and formation of blood vessels (Risau and Flamme, 1995; 
Carmeliet, 2000), and will not be discussed further. Postnatal remodeling traditionally 
occurs via arteriogenesis and/or angiogenesis. Arteriogenesis is defined as the outward 
remodeling of an artery, and angiogenesis refers to growth of new capillaries from pre-
existing ones. Arteriogenesis and/or angiogenesis can occur as a result of various stimuli 
such as muscle stretch or altered flow/shear stress (Zhou et al., 1998; Rivilis et al., 2002; 
Haas et al., 2007). This review will focus on arteriogenesis and angiogenesis within 
skeletal muscle. 
1.3.1: Arteriogenesis of arterioles 
Arteriogenesis was first identified by doctors Fulton and Baroldi in the late 1960s 
within the coronary circulation. Using post mortem angiograms scientists found that 
collateral artery remodeling allowed blood to bypass an occluded vessel thereby avoiding 
an infarction (Schaper, 2009). Alternatively, some define arteriogenesis as the 
arterialization of an existing local capillary bed, which is termed “de novo arteriogenesis” 
(Mac Gabhann and Peirce, 2010). Of interest in the present review is flow-mediated 
remodeling of existing arterioles (Figure 1.2).  
Initially, elevations in blood flow will result in endothelial derived production and 
release of vasodilators culminating in vasodilation within small muscular arterioles. 
Continued elevations in shear stress will elicit outward arterial remodeling (Tronc et al., 
 9!
1996). However, flow-mediated remodeling triggers a negative feedback loop (Schaper, 
2009); thus while augmented shear stress is a potent stimulus for collateralization, it is a 
self-limiting process. Shear stress is inversely related to arterial radius to the fourth 
power. Therefore as the artery remodels to a larger diameter, the magnitude of the shear 
stress is minimized and will no longer be a strong stimulus for continued remodeling 
(Schaper, 2009).   
 
  
Figure 1.2: Structure and composition of an arteriole pre and post arteriogenesis 
 
A) A quiescent arteriole characterized by a monolayer of endothelial cells surrounded by one 
or more layer(s) of smooth muscle cells. Muscle layers are separated from one another by 
elastic lamina and finally by the adventitia. B) Schematic of an arteriole post outward 
remodeling. The remodeling of an arteriole to a larger diameter is due to the proliferation of 
endothelial and smooth muscle cells. 
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Arteriolargenesis is commonly studied using ligation models, which blocks flow 
through conduit arteries thereby generating high flow conditions within neighboring 
collateral arterioles. As well, prazosin treatment can be used as a tool to increase skeletal 
muscle blood flow and study arteriogenesis within small muscular arterioles. Attention 
must be paid to the vessel(s) under investigation.  
Under physiological conditions skeletal muscle arterioles are continuously 
exposed to normal flow and pressure. Conversely, collateral vessels are arteriole-arteriole 
anastomoses that form an alternate flow route and eventually reconnect with large 
adjacent conduit arteries. Under basal conditions collateral arterioles are very small in 
diameter and experience minimal blood flow and pressure (Helisch and Schaper, 2003). 
Differences exist between the impact of alterations in blood flow within skeletal muscle 
arterioles as compared to collateral arterioles. In response to augmented flow, skeletal 
muscle arterioles will experience an increase in shear stress, which will not damage the 
vessel.  However, post ligation, collateral arterioles experience sudden large increases in 
blood flow and pressure, which may elicit damage and induce an inflammatory response 
(Tuttle et al., 2001; Tang et al., 2005; Buschmann et al., 2003). Therefore, it is preferable 
to specify the region and/or vessels under investigation when discussing arteriogenesis.  
Arteriolar remodeling occurs through the following stages; ECM degradation, cell 
proliferation and migration (Heilmann, 2002; Fung and Helisch, 2012). These processes 
will allow small pre-existing arterioles to expand into larger, albeit still small, arterioles 
(Figure 1.2A & B).  
 The first stage, from 0 to 24 hours of high flow, is dominated by the activation of 
transcription factors, growth factors and other cytokines responsible for arteriogenesis.  
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The second stage, from 1 to 3 days post onset of high flow, is predominantly 
characterized by endothelial and smooth muscle cells reentering the cell cycle and 
undergoing proliferation (Heilmann, 2002). During the second stage and throughout the 
entire remodeling process, there is tightly regulated and controlled ECM breakdown via 
proteases, which also aids in ECM release of growth factors.  Binding of these growth 
factors to their cell surface receptors promotes cell proliferation and migration (Lindner 
and Reidy, 1993). For example, the breakdown of the ECM of vascular smooth muscle 
cells allows for continued smooth muscle cell activation and proliferation (Arras et al., 
1998).  Subsequently, the vessel will enter the synthetic phase, so named for the high 
level of protein synthesis; this phase typically takes place from day 3 to 14 post high-flow 
onset.  At the beginning of this stage, proliferation is still high, waning around day 7 
(Couffinhal et al., 1998), and between days 10 to 14 vascular smooth muscle cells regain 
their contractile phenotype (Arras et al., 1998).  The final phase, maturation phase, is 
from day 14 onward.  During this phase the newly enlarged vessel begins to stabilize 
(Scholz et al. 2000) and smooth muscle cells continue to regain their contractile 
phenotype (Arras et al., 1998). The newly enlarged vessel (Figure 1.2B) is now able to 
transport larger volumes of blood to distal tissue.  Outward arteriolar remodeling is 
dependent on the actions of several pro-remodeling factors including: VEGF (Chalothorn 
et al., 2007), placental growth factor (Pipp et al., 2003), matrix metalloproteinases 
(MMP) (Haas et al., 2007) and transforming growth factor-beta (TGF-β) (van Royen et 
al., 2002) (discussed in section 1.4).   
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1.3.2: Angiogenesis 
Angiogenesis (Figure 1.3) is a tightly regulated process that once complete 
augments local tissue perfusion. It has now been well established that within adult tissue 
angiogenesis is seen in response to tissue growth/repair and within the female 
reproductive tract. Aberrant and/or excessive angiogenesis is seen in several diseases 
including diabetic retinopathy, cancer and rheumatoid arthritis (Folkman, 1971; Holmes 
and Zachary, 2005; Adair and Montani, 2011; Wang et al., 2012). Additionally, impaired 
or insufficient angiogenesis is a known complication of diseases including diabetes 
(Martin et al., 2003) and peripheral artery disease (PAD) (Haas et al., 2012). 
Additionally, scientists have attempted to utilize angiogenic therapies to improve the 
outcome of several pathologies including myocardial infarction and PAD (Adair and 
Montani, 2011).  
Angiogenesis was first described in the late 1700s by John Hunter (Skalak, 2005). 
Fifty years after (mid 1800s) the initial discovery by Hunter, Meyer described the 
sprouting of new vessels from pre-existing vessels (Skalak, 2005). Moving forward to the 
early 1900s, Clark first described flow-induced microvessel remodeling, within the 
tadpole tail. As reviewed by Skalak (2005), the work of Dr. Folkman spearheaded our 
understanding of the role of angiogenesis in cancer progression. Furthermore, Dr. 
Hudlicka pioneered the field of skeletal muscle microvascular remodeling (Skalak, 2005).  
Both sprouting and splitting angiogenesis will be discussed in greater detail, as 
they are the two main forms of angiogenesis within adult tissue (Figure 1.3B & C).  
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Figure 1.3: Structure and composition of a skeletal muscle capillary pre and post 
angiogenesis  
 
A) Schematic representation of the composition of a normal capillary, as characterized by 
quiescent endothelial cell(s) connected by junctional proteins such as VE-Cadherin. The 
endothelial cells are surrounded by a basement membrane within which the pericyte(s) are 
located.  
B) Schematic representation of a capillary undergoing sprouting angiogenesis. This form of 
angiogenesis is characterized by basement membrane degradation as well as by stalk/
proliferating endothelial cells and tip/migratory cells.  
C) Schematic representation of vessels undergoing splitting angiogenesis. This form of 
angiogenesis is characterized by the presence of luminal protrusions."
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1.3.2.1: Sprouting angiogenesis 
Sprouting angiogenesis is defined as the budding of endothelial cells from the 
abluminal side of the capillary to form a new capillary (See figure 1.3B). This new “bud” 
will eventually result in the connection of two existing capillaries.  Sprouting 
angiogenesis occurs through the following stages: endothelial cell activation, 
proliferation, proteolysis of the basement membrane, migration and formation of a new 
capillary with an intact basement membrane (Pepper, 1997).   
Endothelial cell activation is the alteration in morphology from a quiescent 
phenotype to one ready to undergo proliferation; proliferation refers to the increase in 
endothelial cell number.  Proteolysis of the endothelial cell basement membrane is due to 
proteases such as MMPs (Haas 2002) allowing endothelial cells to pass through the 
basement membrane and migrate. Lastly, the formation of a stable new capillary is aided 
by the return of endothelial cell pericyte coverage (Egginton et al. 2000). Sprouting 
angiogenesis is thought to be the primary form of angiogenesis seen in response to 
exercise training (Haas, 2002; Roudier et al., 2009; Slopack et al., 2014), muscle stretch 
(Egginton et al., 1998; Milkiewicz et al., 2007; Gorman et al., 2014) and potentially 
hypoxia (Deveci et al., 2001).   
Asides from exercising an animal, stretch induced angiogenesis can be examined 
in vivo by extirpating an agonist muscle, such as the tibialis anterior (TA). This in turn 
exposes the extensor digitorum longus (EDL) muscle to overload induced muscle stretch 
which culminates in angiogenesis (Egginton et al., 1998; Milkiewicz et al., 2007; Gorman 
et al., 2014). Sprouting angiogenesis is mediated by several pro-remodeling factors 
including VEGF, MMPs (Rivilis et al., 2002) and hypoxia inducible factor (HIF) 
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(Milkiewicz et al., 2007).  Sprouting angiogenesis is a rapid process in rodents, with 
increases in C:F evident after as little as 7 days of muscle overload (Gorman et al., 2014) 
or two weeks of treadmill training (Slopack et al., 2014).  
1.3.2.2: Splitting angiogenesis 
Splitting angiogenesis is the division of an existing “parent” capillary into two 
“daughter” vessels (Figure 1.3C) (Egginton and Gerritsen, 2003). This form of 
angiogenesis is known to occur in response to sustained elevations in blood flow/shear 
stress (see review Hudlicka & Brown 2009). Sustained elevation in shear stress 
stimulates an endothelial filiform-like process which transverses the “parent” capillary 
(Figure 1.3C), to create two “daughter” vessels. Rodents treated with prazosin (50mg/L) 
will undergo splitting angiogenesis within 7 to 14 days (Ziada et al., 1989; Zhou et al., 
1998; Milkiewicz et al., 2006; Milkiewicz et al., 2007).  
Splitting angiogenesis requires the coordinated alteration in multiple factors. 
Splitting angiogenesis is known to elicit an increase in VEGF-A expression (Milkiewicz 
et al., 2007) and activity of MAPKs JNK and p38 (Uchida et al., 2008; Gee et al., 2010). 
There is no change in MMP activity with shear stress induced angiogenesis (Milkiewicz 
et al., 2006), which is linked with the apparent lack of basement membrane degradation 
(Egginton et al., 2001). Additionally, shear stress induces an increase in ETS-1 
expression through ERK1/2 dependent signaling (Milkiewicz et al., 2008). Elevated ETS-
1 expression contributes to shear stress dependent increases in the expression of protease 
inhibitors. The shear induced increase in plasminogen activator inhibitor-1 and tissue 
inhibitor of metalloproteinase (TIMP) 1 and 3 in response to elevated shear stress is 
thought to be an important contributor to the lack of migration and proliferation seen with 
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splitting angiogenesis (Milkiewicz et al., 2008). Prazosin cannot exert its pro-angiogenic 
effects in eNOS deficient mice or mice concurrently treated with a NO inhibitor, which 
highlights the importance of NO in shear stress induced angiogenesis (Williams et al. 
2006).  
1.3.2.3: Comparison of splitting and sprouting angiogenesis 
There are several notable differences between splitting and sprouting 
angiogenesis; splitting angiogenesis is thought to have several advantages over sprouting 
angiogenesis. Computational modeling has suggested greater improvement of tissue 
oxygenation with splitting angiogenesis (Ji et al., 2006). As well, splitting angiogenesis is 
more energy efficient than sprouting angiogenesis because splitting angiogenesis does not 
require endothelial cell proliferation, basement membrane degradation or endothelial cell 
migration (Egginton et al., 2001). While the balance between pro and anti angiogenic 
factors as well as between proteases and their inhibitors is essential for both forms of 
angiogenesis (Bode et al., 1999; Olfert and Birot, 2011), there are several notable 
differences. Both splitting and sprouting angiogenesis are associated with increased 
VEGF expression (Milkiewicz et al., 2001; Rivilis et al., 2002; Milkiewicz et al., 2007), 
however only sprouting angiogenesis is associated with increased MMP activity (Rivilis 
et al., 2002). As well, HIF-1α, which has been shown to be important for sprouting 
angiogenesis, is not required for splitting angiogenesis (Milkiewicz et al., 2007). 
Alterations in other growth factors will be discussed in greater detail below (see section 
1.4). 
Although the pericytes will not be discussed in further detail, it is worthy to 
mention that pericytes play a role in the regulation of angiogenesis (Egginton et al., 
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2000). Pericytes have been proposed to have a role in sensing an angiogenic stimulus 
(Gerhardt and Betsholtz, 2003). As well, research has suggested that pericytes aid in 
ECM production or degradation, regulate endothelial cell proliferation and/or 
differentiation and play a role in endothelial cell-cell signaling (Gerhardt and Betsholtz, 
2003). 
1.4: Factors associated with vascular remodeling  
The microvasculature responds to changes within its local microenvironment, 
such as alterations in blood flow, muscle stretch or hypoxia via the modulation of pro-
remodeling and anti-remodeling factors (Pepper, 2001). This tight regulation of the 
microenvironment is required for the appropriate amount of microvascular remodeling to 
occur. A few key regulators secreted by one or more cell types within the 
microenvironment, which are known to be relevant to vascular remodeling, will be 
discussed below in more detail.  
1.4.1: Vascular endothelial growth factor  
VEGF is one of the thoroughly researched pro-angiogenic factors. Although first 
discovered under the name vascular permeability factor (Senger et al., 1983), the name 
VEGF was established shortly thereafter (Ferrara and Henzel, 1989) and became the 
commonly used name.  
It is now known that there are 7 members of the VEGF family: VEGF-A, B, C, D, 
E, F and placental growth factor (Hoeben et al., 2004). VEGF-A is best described for its 
pro-angiogenic functions, therefore it will be the focus in the current review. For the 
remainder of this dissertation the term VEGF will refer to VEGF-A. VEGF-A can 
undergo exon splicing to create multiple splice variants. In humans, this results in the 
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production of VEGF-A121, 145, 165, 183, 189 and 206. Mouse splice variants retain the 
same functional and biological functions, however they are 1 amino acid smaller 
(Vempati et al., 2014). These variants all contains exons 1 to 5 and 8, the splicing takes 
place on exons 6 and 7 (Holmes and Zachary, 2005). There are several differences 
between the different VEGF-A isoforms. For example, VEGF-A isoform 121 is soluble 
and easily diffusible, while 165 contains both soluble and cell bound properties 
(Dehghanian et al., 2014). The ECM attachment of the larger isoforms of VEGF is due to 
heparin binding (Houck et al., 1992). Proteases, such as MMPs or plasmin, cleave matrix 
bound VEGF isoforms and release soluble fragments that are able to exert pro-angiogenic 
effects (Lee et al., 2005).  
Since its initial discovery, a substantial amount of research has been geared 
towards understanding the important role(s) of VEGF.  VEGF is indispensible for 
vascular development and survival; animal studies have proven this point by 
demonstrating that global VEGF deletion in mice is embryonically lethal (Carmeliet et 
al., 1996; Ferrara et al., 1996). VEGF is well known for its ability to increase 
permeability, cell proliferation, migration and survival (Ferrara, 2004) making VEGF 
integral for post-natal angiogenesis (Milkiewicz et al., 2001; Williams et al., 2006; 
Uchida et al., 2015). Williams and colleagues demonstrated that both prazosin and stretch 
induced angiogenesis are abrogated by preventing the actions of VEGF via the VEGF-
Trap (Williams et al. 2006). Additionally, recent work by Haas and colleagues 
demonstrated that a significant decrease in VEGF within the skeletal muscle 
microenvironment abolishes prazosin-induced angiogenesis (Uchida et al., 2015). Taken 
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together these studies demonstrate that VEGF is important for prenatal vascular growth 
and development as well as postnatal remodeling. 
For VEGF to exert its pro-angiogenic effects it must bind to one of its cell surface 
receptors. To date, three VEGF tyrosine kinase receptors (VEGF-R) have been identified: 
fms-like tyrosine kinase-1 or VEGF-R1, fetal liver kinase-1 or VEGF-R2 and fms-like 
tyrosine kinase-4 or VEGF-R3 (Ortega et al., 1999). VEGF-R3 is predominantly located 
within lymphatic endothelial cells (Holmes and Zachary, 2005) and thus will not be 
discussed further. VEGF-R1 and VEGF-R2 are both predominantly expressed on 
vascular endothelial cells (Quinn et al., 1993; Neufeld et al., 1999; Ferrara et al., 2003) 
and to a lesser extent on smooth muscle cells (Ortega et al., 1999; Ishida et al., 2001). 
VEGF-R1 and R2 and are known to be integral for VEGF mediated angiogenesis (Ferrara 
et al., 2003). These two receptors were discovered in the early 1990’s by de Vries and 
Terman respectively (de Vries et al., 1992; Terman et al., 1992). Interestingly, VEGF has 
a greater affinity for VEGF-R1 than VEGF-R2 (Terman et al., 1992; Quinn et al., 1993). 
However, it is VEGF binding to VEGF-R2 that triggers an angiogenic response (Ferrara, 
2004). Within endothelial cells, VEGF-R1 is known to be weakly phosphorylated which 
suggests that this receptor acts as a “decoy” receptor, to prevent angiogenic signaling 
through VEGF-R2 (Lee et al., 2007) (Figure 1.4).  
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Figure 1.4: Schematic representation of endothelial cell VEGF signaling 
 
Schematic representation of endothelial VEGF signaling. 1) VEGF levels can be increased 
due to a variety of stimuli including hypoxia, augmented shear stress, exercise and muscle 
stretch. 2)This increase in VEGF will increase VEGF binding to VEGF-R1 and R2. 
Binding to VEGF-R1 is thought to reduce binding to VEGF-R2, furthermore the cellular 
actions of VEGF binding to VEGF-R1 are not well characterized. Binding of VEGF to 
VEGF-R2 will elicit receptor dimerization. 3) Receptor autophosphorylation is required 
for the subsequent activation of pro-survival and pro-angiogenic factors. This will, for 
example, elicit the phosphorylation of p38. AKT and ERK1/2. 4) Activation of theses, and 
other pro-survival and pro-angiogenic factors, will augment cell survival and angiogenesis 
through several actions including increased cell adhesion, alterations in permeability and 
proliferation.  
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Binding of VEGF to VEGF-R2 will induce receptor dimerization (Mac Gabhann 
and Popel, 2007) (Figure 1.4), which is accompanied by autophosphorylation of several 
tyrosine resides (Wu, 2000).  Receptor dimerization is required for its activation (Mac 
Gabhann and Popel, 2007), while autophosphorylation  allows for the activation of 
downstream signaling pathways (Olsson et al., 2006). VEGF activation and signaling is 
complex and thus in the present review only a few downstream factors will be discussed 
(Figure 1.4). Autophosphorylation of Tyr1175 will result in activation of the ERK 
pathway (Arsham et al., 2002), which is known to be important for a variety of pro-
remodeling actions including proliferation, transcription and cell adhesion (Roskoski, 
2012).  Furthermore, a common downstream target of VEGF binding to VEGF-R2 is the 
activation of Akt (Byzova et al., 2000). Akt activation/phosphorylation can play a role in 
a variety of functions integral for angiogenesis including cell growth and proliferation 
(Manning and Cantley, 2007). As well, the MAPK p38, is a downstream target activated 
by VEGF binding toVEGF-R2 (Olsson et al., 2006; Lamalice et al., 2007; Gee et al., 
2010). Furthermore, p38 is required for splitting angiogenesis (Gee et al., 2010) and 
exerts several pro-angiogenic functions including cellular migration via stress fiber 
formation (Lamalice et al., 2007) and increased vascular permeability (Olsson et al., 
2006).  
Within the skeletal muscle microcirculation, VEGF expression is known to be 
increased in response to a variety of stimuli: exercise (Gustafsson et al., 2001), muscle 
overload (Rivilis et al. 2002; Williams et al. 2006), elevated shear stress (Milkiewicz et 
al., 2001; Rivilis et al., 2002) and hypoxia (Forsythe et al., 1996; Brown et al., 2003; 
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Breen et al., 2008). Below, hypoxia and shear stress stimuli will be discussed in greater 
detail.  
Hypoxia is a potent stimulus for increased VEGF expression (Breen et al., 2008). 
The VEGF gene contains a hypoxic response element within its promoter region to which 
HIF1α and HIF1β bind, allowing for increased VEGF transcription (Forsythe et al., 
1996).   Briefly, HIF1α is rapidly degraded under normoxic conditions but becomes 
stabilized under hypoxic conditions (Kallio et al., 1999). Additionally, hypoxia will result 
in the generation of reactive oxygen species (ROS) as well as MMP9, both of which will 
increase VEGF mRNA (Arbiser et al., 2002). It is through these signaling pathways that 
hypoxia is thought to alter the microvascular microenvironment and create a pro-
angiogenic environment subsequently resulting in capillary growth (Breen et al., 2008). 
Augmented blood flow or shear stress induces an increase in VEGF (Milkiewicz et al. 
2001; Williams et al. 2006), which occurs alongside an increase in NO (Milkiewicz et al., 
2001). NO, a potent vasodilator, is important in VEGF signaling (Papapetropoulos et al., 
1997). Augmented VEGF-A expression in response to hypoxia or increased flow is 
integral for the maintenance of vascular health and/or remodeling.  
Elevated VEGF levels are integral for the process of vascular remodeling. 
Research has shown that the peak increase in VEGF precedes the increase in C:F (Rivilis 
et al., 2002; Milkiewicz et al., 2007). VEGF mRNA and protein analyzed from whole 
muscle lysates post prazosin treatment revealed that the increase in VEGF was seen after 
2 days while no increase in C:F is seen till day 7 (Rivilis et al., 2002). In response to 
muscle stretch, a tool used to elicit and examine sprouting angiogenesis, VEGF 
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expression is increased by day 7 but no increase in C:F is seen until day 14 (Milkiewicz 
et al., 2007).  
Within the microenvironment of the microcirculation, VEGF can be produced by 
several different cell types including: myocytes, vascular smooth muscle cells, 
endothelial cells, or pericytes (Milkiewicz et al., 2001; Darland et al., 2003). Alterations 
in VEGF production, from one or more of the above cell types, will impact the 
microenvironment and subsequently microcirculatory health and function. In recent years 
researchers have been interested in uncovering which cell type or types within the 
microenvironment is/are primarily responsible for VEGF production required for 
vascular remodeling. This was explored using inducible models of endothelial or smooth 
muscle cell specific VEGF deletion. Interestingly, recent studies have suggested that it is 
skeletal muscle cell derived VEGF (Olfert et al., 2010; Delavar et al., 2014; Uchida et al., 
2015) and not endothelial derived VEGF (Lee et al., 2007) that is responsible for both 
sprouting and splitting angiogenesis (Olfert et al., 2010; Delavar et al., 2014; Uchida et 
al., 2015). Endothelial cells will detect alterations in flow and respond by increasing NO 
production and secretion, which will subsequently stimulate myocyte production and 
release of VEGF. In turn, myocyte derived VEGF will be secreted into the 
microenvironment, stimulate endothelial cells finally resulting in angiogenesis (Uchida et 
al., 2015). These findings highlight the complexity of cellular communication within the 
microenvironment regulating vascular remodeling.  
VEGF also plays a role in other forms of vascular remodeling including 
arteriogenesis and capillary rarefaction. Arteriogenesis requires VEGF as shown by the 
fact that the lower levels of VEGF in BalB/c mice is responsible for their decreased 
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collateralization, as compared to C57Bl/6 mice which have higher VEGF levels 
(Chalothorn et al., 2007). Additionally, VEGF-R antagonism will inhibit collateral vessel 
arteriogenesis (Lloyd et al., 2005), and newly formed/remodeled vessels will not mature 
and will be pruned away if VEGF levels are low (Hanahan, 1997). Some reports have 
shown that capillary regression is the result of a decrease in VEGF (Bey et al., 2003) or 
VEGF-R2 (Wagatsuma, 2008; Roudier et al., 2010) protein levels. Taken together these 
studies highlight the importance of VEGF in multiple different forms of skeletal muscle 
microvascular remodeling.  
1.4.2: Thrombospondin-1 
TSP-1 is a large matrix glycoprotein (MW 450kDa), which was first isolated from 
the human placenta in a study concluded in 1978 (Lawler et al., 1978). Within 10 to 12 
years of its initial discovery, TSP-1 was the first protein to be classified as an endogenous 
inhibitor of angiogenesis (Good et al., 1990). While TSP-1 is not the only anti-angiogenic 
factor, it remains the most commonly investigated one (Malek and Olfert, 2009). Within 
the microenvironment TSP-1 can be produced by vascular smooth muscle, endothelial 
cells and is found within the extracellular matrix of skeletal muscle (Mosher, 1990). TSP-
1 has been shown to inhibit angiogenesis as well as modulate endothelial cell survival 
through VEGF-dependent and independent mechanisms.  
TSP-1 can inhibit angiogenesis by altering VEGF-A expression and/or actions. 
This can occur by TSP-1 directed inhibition of proteolytic enzymes (Hogg, 1994) such as 
MMPs, thus minimizing VEGF release from the ECM (Lee et al., 2005). As well, TSP-1 
can bind directly to VEGF, thereby controlling VEGF removal from the 
microenvironment and limiting its pro-angiogenic actions (Greenaway et al., 2007). TSP-
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1 can bind and activate the cell surface receptor CD36, which subsequently reduces 
VEGF-A function by altering VEGF-R2 and/or p38 MAPK phosphorylation (Primo et 
al., 2005). Furthermore, TSP-1 can counter regulate the pro-angiogenic actions of VEGF-
A through activation of FAS ligand, a pro-apoptotic cytokine (Yano et al., 2003). Taken 
together, these studies highlight the roles of TSP-1 in inhibiting VEGF-A expression and 
function within the microenvironment.  
TSP-1 can inhibit angiogenesis independently of VEGF. TSP-1 can inhibit cell 
cycle progression through interactions with CD36, resulting in cell arrest at the G0/G1 
phase (Armstrong et al., 2002) and thus decreasing endothelial cell proliferation 
(Bagavandoss and Wilks, 1990).  TSP-1 may impair cell cycle progression via reduced 
Akt expression/activation (Oganesian et al., 2008), which could reduce several types of 
microvascular remodeling that are dependent on cell proliferation (arteriogenesis, 
sprouting angiogenesis). TSP-1 can also decrease cell adhesion (Murphy-Ullrich and 
Höök, 1989) and endothelial cell migration, through the cell surface receptor CD36 
(Simantov and Silverstein, 2003). Furthermore, TSP-1 has been shown to directly block 
the pro-angiogenic actions of NO, through interactions with CD36 or CD47 (Roberts et 
al., 2007). TSP-1 may be inhibiting the pro-angiogenic actions of NO through myristic 
acid (Isenberg et al., 2007), a fatty acid thought to be important for nitric oxide synthase 
(NOS) activation and therefore NO signaling (Zhu and Smart, 2005). TSP-1 has been 
shown to play a role in regulating endothelial cell apoptosis, independent of VEGF 
signaling (Jiménez et al., 2000). These pro-apoptotic effects are thought to occur through 
alterations in c-Jun N terminal kinase, commonly referred to as JNK, expression (Jiménez 
et al., 2001). TSP-1 can also mediate apoptosis via increasing Bax, an apoptosis 
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promoter, expression while concurrently reducing Bcl-2, a apoptosis inhibitor, expression 
(Nör et al., 2000). The anti-angiogenic and pro-apoptotic functions of TSP-1 has 
generated interest in using TSP-1 therapies as a treatment option for various types of 
cancers (Zhang and Lawler, 2007). 
 Alterations in TSP-1 expression are linked with changes in vascularity. Increased 
TSP-1 expression is seen in type I diabetes (Kivelä et al., 2006), PAD (Roudier et al., 
2013) and with elevated GCs (Logie et al., 2010), all of which are associated with 
reduced vascularity. As well, TSP-1 null mice have been shown to have increased 
skeletal muscle capillarization, as compared to wild-type (WT) controls (Malek and 
Olfert, 2009). The contrasting pro and anti-angiogenic roles of VEGF and TSP-1 are 
summarized in Figure 1.5.   
VEGF-A TSP1 
Increase C:F Decrease C:F 
Cell survival and proliferation 
- Activation of Akt 
Cell apoptosis 
- Inhibition of Akt 
Increase nitric oxide Reduced nitric oxide 
Activation of MMP2 and 9 Inhibition of MMP9 
Figure 1.5: Summary of the effects of VEGF-A and TSP-1 on the microvasculature 
 
VEGF-A is the most commonly examined pro-angiogenic and arteriogenic factor. VEGF-
A can exert a variety of pro-survival and remodeling actions within the 
microenvironment. Conversely, TSP-1 is the best-characterized anti-angiogenic factor, 
known to impede remodeling and cell survival. (See text for complete details and 
references) 
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1.4.3: Matrix Metalloproteinases and tissue inhibitor of metalloproteinases  
The MMP family consists of over 20 zinc and calcium-dependent proteases.  
MMPs were first described to be involved in the process of basement membrane 
degradation in the early 1980s (Kalebic et al., 1983). It is now known that MMPs are 
secreted as latent enzymes (pro-MMPs), which are activated by the cleavage of their 
amino terminal pro-peptide. MMPs are classified as matrilysins, collagenases, 
stromelysins, membrane type and gelatinases. Overall, MMPs are important for 
endothelial cell attachment, migration, invasion, proliferation and apoptosis (Haas 2002).  
This review will specifically focus on gelatinases, MMP2 and MMP9, which have been 
found to be especially important for vascular remodeling. 
MMPs are produced by a variety of cells within the microenvironment of the 
microcirculation including endothelial cells (Haas et al. 1998), smooth muscle cells 
(Shofuda et al. 2001) and monocytes/macrophages (Haug et al., 2004). Additionally, 
other pro-remodeling factors, including NO (Wang et al., 2004) and ERK 1/2 (Boyd et 
al., 2005) can regulate MMP2 levels.  
Correct alteration in MMP expression and activity are important for various forms 
of vascular remodeling. Increased expression and activity of MMPs is a requisite for 
sprouting angiogenesis (Haas et al., 2000; Rivilis et al., 2002) allowing for basement 
membrane degradation (Pepper, 2001). Additionally, increased MMP activity will permit 
the release of ECM anchored VEGF (Haas, 2002) and other growth factors such as basic 
fibroblast growth factor (Pepper, 2001). The importance of MMPs in sprouting 
angiogenesis was validated by the finding that GM6001 administration, a broad spectrum 
MMP inhibitor, prevented muscle stimulation mediated angiogenesis (Haas et al., 2000). 
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Conversely, with splitting angiogenesis MMP2 expression and activity is not upregulated 
by augmented shear stress (Rivilis et al., 2002) due in part to the shear stress induced 
increase in NO (Milkiewicz et al., 2006) or potentially TIMP1 (Milkiewicz et al., 2008; 
Uchida and Haas, 2014). Lastly, arteriogenesis requires increased MMP activity; 
inhibition of MMP activity via doxycycline treatment inhibits outward arterial 
remodeling (Haas et al., 2007).  Furthermore, MMP2 or MMP9 deficient mice have 
reduced arteriogenesis (Cheng et al., 2007; Huang et al., 2009). These studies highlight 
the importance of regulating MMP expression and activity for appropriate vascular 
remodeling. 
TIMPs are the endogenous inhibitors of the proteolytic activity of MMPs (Brew et 
al., 2000; Snoek-van Beurden and Von den Hoff, 2005; Ries, 2014).  There are four 
known TIMPs, TIMP1, 2, 3 and 4.  TIMPs differ from one another in several regards: 
their interaction and/or activation of pro-MMPs, solubility and expression. TIMP2, 3 and 
4 can cleave the pro-domain of MMP2, while TIMP1 and 3 can cleave and activate pro-
MMP9 (Brew and Nagase, 2010). With regards to solubility, TIMPs 1, 2 and 4 are 
soluble while TIMP3 is not and is found bound to the ECM. Other important differences 
include the fact that TIMP2 and 3 can inhibit membrane type MMPs and TIMP1 and 3 
can inhibit the actions of ADAMs  (a disintegrin and metalloproteinase, a sister enzyme 
to MMPs) (Lambert et al., 2004).  The present dissertation will focus on the role of 
TIMP1 within the microvasculature.  
The MMP dependent functions of TIMPs classify them as inhibitors of 
angiogenesis/vascular remodeling; however the story is far more complex. The ratio of 
TIMPs to MMPs is thought to be important for the regulation of basement membrane 
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proteolysis (Chirco et al., 2006).  Greater MMP activation, relative to TIMPs, results in 
excessive proteolysis; this would impede vascular remodeling as the necessary 
scaffolding for cellular movement is absent (Montesano et al., 1990). Conversely, 
insufficient proteolysis will inhibit cell invasion and subsequent new vessel lumen 
formation (Pepper et al., 1990). Furthermore, overproduction of MMPs is known to cause 
tissue destruction associated with inflammatory disease (Konttinen et al., 1999; Tetlow et 
al., 2001) and many human cancers (Galis and Khatri, 2002; Creemers et al., 2001).  
These findings emphasize that TIMPs are not simply anti-angiogenic, rather they are 
important regulators of relative MMP expression and activity. The appropriate balance 
between TIMPs and MMPs insures appropriate vascular remodeling responses to a given 
stimulus.  
It should be noted that TIMPs may exert MMP independent functions on various 
cellular processes (reviewed in, Ries 2014). For example, within myeloid cells, TIMP1 
has been shown to promote cell survival and proliferation through MAPK and Akt 
pathways (Lambert et al., 2004). Interaction of TIMP1 with the cell surface receptor 
CD63 is linked with suppression of apoptosis (Liu et al., 2005).  Conversely, TIMP1 has 
been reported to induce cell cycle arrest in epithelial cells by decreasing cyclin D1 and 
increasing p27 (Taube et al., 2006).  
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1.5: Research models to manipulate the microvascular microenvironment 
 The microenvironment is recognized as being important, however little is 
currently known regarding the impact of changes to the microenvironment on the 
microvasculature. My dissertation involves utilizing multiple methods to manipulate the 
microenvironment and subsequently examine the consequences on the microvasculature. 
Flow is an integral physiological stimulus that can be used to assess normal endothelial 
cell responses required for remodeling. I have chosen to study the influence of changes in 
skeletal muscle blood flow through either femoral artery (FA) ligation or continuous 
prazosin treatment in rodents. The microenvironment will be manipulated via the deletion 
of TIMP1 or GC excess. The deletion of TIMP1 will be used to assess the impact of 
manipulating the proteolytic balance within the microenvironment. Lastly, sustained 
elevations in circulating corticosterone (CORT), a synthetic GC, will be used due to its 
known rarefactory effects on the microvasculature (Shikatani et al., 2012). These models 
each provide distinct and important information regarding microvascular health and 
overall cardiovascular health. 
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1.5.1 Femoral artery ligation: A model of high and low flow 
 Conduit artery ligation is an experimental tool used to mimic PAD (Lotfi et al., 
2013; Krishna et al., 2016). In humans, PAD develops as a result of atherosclerotic 
plaque formation within large conduit arteries. The most commonly affected vessels are 
those of the lower limb, such as the popliteal, femoral or iliac arteries. As well, PAD is a 
common secondary complication of other diseases such as type-2 diabetes (Ziegler et al. 
2010).  
 Ligation studies are typically performed on small mammals such as rodents and 
rabbits. Currently numerous different strategies are employed to generate hind-limb 
ischemia. Some research groups utilize a single ligation of the femoral or iliac artery, 
leaving the venous circulation and nervous tissue undisturbed (Brevetti et al., 2001; 
Milkiewicz et al., 2011; Roudier et al., 2013), which is proposed to represent intermittent 
claudication (Lotfi et al., 2013). Others have used excision of the FA (Murohara et al., 
1998; Cheng et al., 2007; Huang et al., 2009), which is thought to more closely mimic 
human critical limb ischemia (Lotfi et al., 2013). Using the single ligation model is 
beneficial as it does not result in an inflammatory response or tissue necrosis (Hudlicka et 
al., 1994; Milkiewicz et al., 2006), and thus it was used in the current project.  
 FA ligation generates two distinct areas (Figure 1.6); below the ligation site is a 
low flow region, while parallel to the ligation area is a non-ischemic region of elevated 
flow (Shireman and Quinones, 2005).  Different forms of vascular remodeling are 
proposed to occur within each of these regions. 
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Figure 1.6: Schematic of rodent lower limb vasculature and the impact of femoral 
artery ligation 
 
Ligation of the femoral artery will create two distinct zones. Parallel to the site of 
ligation, there is a non-ischemic region, which encompasses the collateral vessels. Distal 
to the site of ligation is the hypoxic/ischemic region.  
 
1.5.1.1: Microvascular responses distal to the site of ligation: reduced flow  
 The region distal to the site of obstruction exhibits reductions in blood flow as 
well as increased metabolic and hypoxic stress. Sustained reduction in blood flow/shear 
stress is known to result in microvascular rarefaction (Triantafyllou et al., 2015). At the 
arteriolar level, reduced blood flow elicits a decrease in luminal diameter; the 
consequence of which is a chronic increase in resistance and an overall reduction in 
downstream/distal perfusion (Pourageaud and De Mey, 1997). At the capillary level, 
insufficiently perfused capillary beds will result in capillary rarefaction, or the loss of 
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existing capillaries. Capillary rarefaction is seen in several diseases including diabetes 
(Benedict et al., 2011) and hypertension (Vogt and Schmid-Schobein, 2001). 
Microvascular rarefaction may be due to a decrease in pro-angiogenic factors such as 
VEGF (Bonner et al., 2013) and angiopoietin-1 (Ang-1) (Wagatsuma, 2008) or an 
increase in anti-angiogenic factors such as TSP-1 (Olfert, 2015).  
 The loss of skeletal muscle microvasculature will decrease oxygen and nutrient 
delivery to the muscle, thereby effecting exercise ability (Haas et al., 2012) and 
potentially insulin sensitivity (Akerstrom et al., 2014). Microvascular rarefaction has 
been shown to play a key role in the pathophysiology of hypertension (Humar et al., 
2009). This situation elicits a vicious circle; microvascular rarefaction increases 
peripheral resistance (Greene et al., 1989) thereby further reducing blood flow and 
elevating systemic blood pressure (Humar et al., 2009). Additionally, hypertension is a 
potent stimulus for capillary rarefaction (Hansen-Smith et al., 1996).   
 Hypoxia is likely present distal to the site of occlusion, which generates a potent 
angiogenic stimulus (Westvik et al. 2009). Although a pro-angiogenic environment is 
present within the microcirculation, the occurrence of an angiogenic response remains 
controversial. Some studies have shown angiogenic adaptations to hind-limb ischemia 
(Ito et al. 1997; Couffinhal et al. 1998; Westvik et al. 2009), while others have not 
(Scholz et al., 2002; Milkiewicz et al., 2011; Roudier et al., 2013). These different reports 
could be due to methodological differences within the studies. Some studies reported C:F 
and others reported capillary density (CD) as measurements of angiogenesis. However, 
CD may be an inaccurate inference of angiogenesis because it can be confounded by 
changes in muscle fiber cross-sectional area as well (Roudier et al., 2010). Secondly, the 
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various studies reported used different species or strains for experimentation. This needs 
to be accounted for, as there are species/strain differences in the size and quantity of 
existing collateral routes. Lastly, we must consider whether the ligation model used will 
elicit an inflammatory response, which is a potent stimulator of angiogenesis (Zhuang et 
al., 2011). As well, angiogenesis may be inhibited due the increased expression of the 
anti-angiogenic factor FoxO1 in response to ischemia (Milkiewicz et al., 2011).  
1.5.1.2: Microvascular responses parallel to the site of ligation: elevated flow  
Adjacent to the ligation site is a normoxic region (Figure 1.6) in which arteriogenesis 
occurs (Shireman and Quinones, 2005).  Due to the blockage of the conduit vessel, blood 
is diverted through collateral routes; this increase in blood flow through the collateral 
arterioles is a potent arteriogenic stimulus (Ziegler et al., 2010) (Figure 1.7A & B). 
Collateralization is thought to be the primary method of restoring blood flow to an 
ischemic area (Scholz et al. 2002). Alterations in pro-remodeling factors/signaling 
pathways mediates adaptive collateralization; altered factors/pathways include: NO (Dai 
and Faber, 2010), ERK (Lanahan et al., 2010) and PI3K/Akt and Src (Tzima et al., 2005), 
see section 1.3.1 for further details.  As well, it should be reiterated that there is the 
possibility of immune cells contributing to collateralization (see section 1.3.1) (Tuttle et 
al., 2001; Buschmann et al., 2003; Fung and Helisch, 2012). In vivo, arteriogenesis can be 
examined directly through angiography or corrosion casting, or indirectly via laser 
Doppler flow assessments.  
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Figure 1.7: Schematic representation of collateral vessel remodeling in response to 
femoral artery ligation 
 
Collateral arteriogenesis is proposed to occur within the normoxic region of animals that 
underwent femoral artery ligation. This allows previously small and minimally perfused 
vessels (A) to remodel to a larger diameter (B) and therefore provide a route for blood to 
bypass the occlusion and reach the distal hypoxic tissue.  
 
In the current project, unilateral FA ligation was performed in both WT and 
TIMP1 deficient mice (Timp1-/-).  We chose Timp1-/- mice because this should in theory 
shift the balance between proteases (MMPs) and their inhibitors (TIMPs) within the 
microenvironment of the microcirculation. This method provides a tool to examine the 
importance of TIMP1 and the proteolytic balances on vascular remodeling to both 
reduced and elevated blood flow. 
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1.5.2: Prazosin- a model of elevated skeletal muscle blood flow  
 Prazosin is an α-1 adrenergic receptor (α1-AR) antagonist that first came on to 
the market in the 1970’s as a treatment for hypertension. α1-ARs are a class of G-protein 
coupled receptors known to modulate responses to the actions of catecholamines and are 
primarily located at the arteriolar level of the vascular tree. Resting skeletal muscle 
vasculature is generally constricted due the release of norepinephrine from sympathetic 
neurons, which binds to α1-ARs. The blockade of this system by prazosin elicits vascular 
dilation, primarily within the skeletal muscle vasculature, due to the high prevalence of 
α1-AR on smooth muscle cells of this microcirculation (Piascik et al., 1990). It should 
also be noted that prazosin has been shown to have beneficial roles in lowering total 
serum cholesterol, LDL and total triglycerides (Leren, 1984). As well, human studies 
have demonstrated that prazosin treatment may help improve insulin resistance (Pollare 
et al., 1988; Swistocki et al., 1989). 
 Animal studies have calculated that resting skeletal muscle capillary shear stress 
is around 5 dynes/cm2, which increases roughly threefold to 15 dynes/cm2 with prazosin 
treatment (Milkiewicz et al., 2001). While prazosin induces skeletal muscle vasodilation, 
no significant reductions in mean arterial pressure were noted (Milkiewicz et al., 2001). 
Animal studies traditionally administer prazosin via dissolution in the drinking water, 
which insures continuous drug delivery, as prazosin has a relatively short half-life of 
around 2.5 hours (Jaillon, 1980).  
 In my dissertation I used prazosin treatment, which is a useful tool to assess 
alterations to shear mediated signaling pathways. Prazosin treatment was used in 
conjunction with TIMP1 deletion or elevated GCs, as a tool to evoke flow-induced 
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remodeling, as has been well established to occur in healthy animals (Ziada et al., 1989; 
Zhou et al., 1998; Milkiewicz et al., 2007; Uchida and Haas, 2014). 
1.5.3: Glucocorticoids  
GCs are a class of cholesterol derived steroid hormone secreted by the adrenal 
glands and are essential for survival. Within humans, the primary GC is known as cortisol 
while in rodents it is called CORT. GCs are regulated by both a circadian rhythm and are 
produced in response to stress. Typically, GCs (natural and synthetic) transduce their 
effects through binding to the glucocorticoid receptor (GR) (Figure 1.8).  
 
 
 
Figure 1.8: Local cellular effects of glucocorticoids  
 
Schematic representation of the cellular effects of GCs. GC will diffuse easily into a cell, 
due to their lipophilic nature. Once in the cytosol, GC will bind to the GC-receptor (GR) 
after which the complex will translocate to the nucleus to exert transcriptional effects via 
binding to the glucocorticoid response element. Additionally, GC can remain in the 
cytoplasm to exert additional affects. 
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 Once GC bind to the GR, the complex will translocate to the nucleus where GCs 
can exert their genomic effects such as transcriptional activation or repression, on a vast 
array of target genes (Oakley and Cidlowski, 2011). These actions are the result of 
binding to glucocorticoid response elements found within the promoter or intragenic 
region of GC target genes (Kadmiel and Cidlowski, 2013).  
GCs are known to impact angiogenesis within various tissues, including bone 
(Weinstein et al., 2010), aortic ring preparations (Small et al., 2005) and skeletal muscle 
(Shikatani et al., 2012). In the current project, pathophysiological levels of GCs were 
used as a tool to examine skeletal muscle microvascular responsiveness to pro-
remodeling cues within the microenvironment.  
Several studies have provided insight into potential mechanisms underlying GC-
mediated inhibition of angiogenesis and induction of capillary rarefaction.  For example, 
sustained exposure to a pathophysiological level (600nM) of CORT was shown to inhibit 
endothelial cell proliferation and migration, key cellular events in the process of 
angiogenesis (Small et al., 2005; Shikatani et al., 2012). CORT has been shown to reduce 
VEGF mRNA levels (Shikatani et al., 2012; Ullian, 1999), NO bioavailability (Ullian, 
1999; Rogers et al., 2002) and other pro-angiogenic factors including MMP2, RhoA and 
phospho-ERK1/2 (Shikatani et al., 2012). Furthermore, GCs may augment the expression 
of potent anti-angiogenic factors such as FoxO1 (Shikatani et al., 2012) and TSP-1 
(Barclay et al., 2016).  
There is evidence to suggest that ROS levels may be elevated due to GC-
treatment (Zhang et al., 2004). ROS are produced by a variety of cellular processes 
including, mitochondrial respiration (Han et al., 2001), NADPH oxidase (Nauseef, 2008), 
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xanthine oxidase (Garattini et al., 2003), as well as via eNOS uncoupling (Marchesi et al., 
2009). Within the vasculature, there is a physiological role for moderate levels of ROS on 
the regulation of vascular tone (Zhang and Gutterman, 2007) and angiogenesis (Abid et 
al., 2007; Frey et al., 2009). However, excessive levels of ROS has been shown to play a 
pivotal role in the development of hypertension (Montezano and Touyz, 2014) and 
insulin resistance (Anderson et al., 2009; Houstis et al., 2006; Furukawa et al., 2004; 
Haber et al., 2003). In vivo, circulating ROS levels can be reduced with Tempol 
treatment. Briefly, Tempol is a stable, cell permeant piperidine nitroxide that acts as a 
superoxide dismutase mimetic (Wilcox and Pearlman, 2008). Tempol has been shown to 
reduce blood pressure and to protect lipids and proteins from oxidative damage 
(Schnackenberg et al., 1998; Schnackenberg and Wilcox, 1999; Damiani et al., 2000).  
Recently our laboratory has shown that GC excess results in skeletal muscle 
capillary rarefaction (Shikatani et al., 2012); however, the precise mechanisms 
responsible for the phenotype are currently unknown. Capillary rarefaction may in turn 
be an important contributor of GC induced hypertension (Staiculescu et al., 2014). 
Additionally, recent research has reported a link between capillary content and skeletal 
muscle insulin and glucose handling (Akerstrom et al., 2014). Therefore, it stands to 
reason that GC-mediated rarefaction may impact insulin sensitivity. Lastly, sustained 
elevations in circulating GC levels results in dysfunctional glucose handling, whole body 
insulin resistance and skeletal muscle atrophy (Shpilberg et al., 2012; Yuen et al., 2013). 
The rodent model of elevated GC levels significantly impacts the microcirculation 
(Shikatani et al., 2012) as well as mimics the phenotype of metabolic syndrome and/or 
type-2 diabetes (Shpilberg et al., 2012).  
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1.6: Scope of the dissertation 
 
 The current studies used several different models to assess how pathological 
alterations to the microenvironment will impact microvascular content and flow-induced 
remodeling (Figure 1.9). TIMP1 deletion and GC excess are the two different 
perturbations used to alter the microenvironment, which were used in conjunction with 
prazosin or FA ligation. Examining alterations to the microenvironment in response to 
FA ligation is of interest for researchers hoping to gain preclinical information on 
important signaling pathways and mechanisms to be considered. Both prazosin and FA 
ligation modulate hind-limb blood flow thereby providing a tool to examining how 
alterations in TIMP1 expression or GC levels within the microenvironment will 
subsequently affect the microvasculature’s ability to remodel in response to physiological 
signaling (Table 1).  
Table 1.1: Models used to alter flow both in vivo and in vitro 
 
Models used to Increase 
flow 
 Models used to lower flow 
Duration of Treatment 
Prazosin Treatment 1 to 2 weeks  
Femoral artery ligation 4,7, 14, or 21 days Femoral artery ligation: 
ischemic region 
In vitro: Shear stress 2 or 24 hours In Vitro: low shear stress 
 1 to 2 weeks Glucocorticoid treatment 
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Figure 1.9: Schematic representation of the scope of the dissertation 
 
A stable microvascular network requires a balance in pro-survival/angiogenic factors and 
pro-apoptotic/anti-angiogenic factors.  Alterations in blood flow is known to result in 
microvascular remodeling (solid black lines). Increased blood flow, as seen in response to 
FA ligation or prazosin treatment will elicit arteriogenesis and angiogenesis. Conversely, a 
reduction in flow will elicit microvascular rarefaction. The current study will examine how 
elevated GC levels or a loss of TIMP1 (dashed lines) will impact the microvasculature and 
its responses to alterations in blood flow.  
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The first study was aimed at uncovering the importance of TIMP1 expression on 
vascular remodeling. TIMP1 regulates proteases activity within the microenvironment 
and flow induced remodeling requires the tight regulation of proteolysis. Therefore, WT 
and Timp1-/- animals were subjected to prazosin treatment or FA ligation to examine how 
alterations in TIMP1 expression affect microvascular remodeling. Cell culture models 
were also employed to more closely examine endothelial cell specific alterations in TIMP 
and/or MMP expression in response to alterations in shear stress. Lastly, I aimed to 
identify mechanisms through which sustained elevations in GC negatively impact the 
microenvironment and subsequently blood pressure. Co-treatment with prazosin was used 
to study endothelial cell shear responsiveness under the negative effects of CORT (Figure 
1.9). Although Timp1-/- and GC excess are very different models, they each provide a 
unique manipulation of microvasculature. These manipulations will provide further 
insight into the intricacies of the microenvironment and the subsequent impact on 
peripheral microvascular health and adaptability. Alterations to the skeletal muscle 
microcirculation can in turn affect CV health, making this an important area of research.  
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I performed all the experiments pertaining to femoral artery ligation in WT and Timp1-/- 
mice (Figures 2.1-2.4). As well, I performed all of the mRNA analysis from the prazosin 
treatment component of the study (Figures 2.6B & C, 2.7B & C). The prazosin-
experiments were performed by Cassandra Uchida with the help of Emmanuel Nwadozi 
(Table 2.1, Figures 2.5, 2.6A, 2.7A, D & E). !
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Chapter Summary:  
Remodeling of the skeletal muscle microvasculature involves the coordinated actions of 
matrix metalloproteinases (MMPs) and their endogenous inhibitors, tissue inhibitor of 
metalloproteinases (TIMPs). We hypothesized that the loss of TIMP1 would enhance 
both ischemia and flow-induced vascular remodeling by increasing MMP activity.  
TIMP1 deficient (Timp1-/-) and wild-type (WT) C57BL/6 mice underwent unilateral 
femoral artery (FA) ligation or were treated with prazosin, an alpha-1 adrenergic receptor 
antagonist, in order to investigate vascular remodeling to altered flow. Under basal 
conditions, Timp1-/- mice had reduced microvascular content as compared to WT mice.  
Furthermore, vascular remodeling was impaired in Timp1-/- mice.  Timp1-/- mice 
displayed reduced blood flow recovery in response to FA ligation and no arteriogenic 
response to prazosin treatment. Timp1-/- mice failed to undergo angiogenesis in response 
to ischemia or prazosin, despite maintaining the capacity to increase VEGF-A and eNOS 
mRNA. Vascular permeability was increased in muscles of Timp1-/- mice in response to 
both prazosin treatment and FA ligation, but this was not accompanied by greater MMP 
activity. This study highlights a previously undescribed integral role for TIMP1 in both 
vascular network maturation and adaptations to ischemia or alterations in flow.  
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Introduction:  
Tissue inhibitors of metalloproteinases (TIMPs) play an integral role in regulating 
extracellular matrix (ECM) turnover (Ries, 2014). Their functional effects are primarily 
thought to occur via inhibition of matrix metalloproteinase (MMP) activity (Brew et al., 
2000; Snoek-van Beurden and Von den Hoff, 2005; Ries, 2014). Appropriately controlled 
increases in expression/activity of MMPs relative to TIMPs facilitate normal ECM 
turnover, which is considered to be an important aspect of vascular remodeling processes 
(Chirco et al., 2006). However, excessive MMP activity may result in a disproportionate 
extent of ECM proteolysis, having pathological consequences (Chirco et al., 2006). Mice 
deficient in TIMP1 exhibit several cardiovascular-associated phenotypes suggestive of 
excessive proteolysis, including a propensity to develop aneurysms, altered myocardial 
remodeling after infarction, and increased vascular permeability and inflammation in the 
lungs in response to injury (Kim et al., 2005; Eskandari et al., 2005; Ikonomidis et al., 
2005). 
The vasculature adapts to sustained alterations in blood flow. At the arterial level, 
sustained reductions in flow results in inward arterial remodeling (Sullivan and Hoying, 
2002; Dumont et al., 2014).  Conversely, arteries and arterioles respond to a sustained 
augmentation in blood flow via arteriogenesis, or outward remodeling, to increase lumen 
diameter (Langille, 1996; De Mey et al., 2005; Heil et al., 2006). MMP activity is 
required for flow-induced outward remodeling of mesenteric arteries (Haas et al., 2007).  
Likewise, the deletion of MMP2 or 9 impairs the process of collateral artery remodeling 
in response to femoral artery (FA) ligation (Cheng et al., 2007; Huang et al., 2009). These 
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findings highlight the importance of appropriate MMP levels for flow-induced artery 
remodeling.  
At the capillary level, a sustained reduction in flow results in capillary rarefaction 
(Triantafyllou et al., 2015), while a chronic increase in flow evokes splitting, or 
intussusceptive, angiogenesis (Ziada et al., 1989; Zhou et al., 1998; Rivilis et al., 2002; 
Milkiewicz et al., 2006; Milkiewicz et al., 2007; Hudlicka and Brown, 2009; Gee et al., 
2010). Splitting angiogenesis occurs via internal division of capillary segments and is not 
characterized by basement membrane degradation (Zhou et al. 1998).  Flow stimulation 
of endothelial cells reduces the production of MMP2 while increasing TIMP1 (Rivilis et 
al., 2002; Milkiewicz et al., 2008; Uchida and Haas, 2014) suggesting that restraint of 
MMP activity may facilitate splitting angiogenesis, by inhibiting the proteolytic 
processes associated with abluminal sprouting.   
We therefore hypothesized that the loss of TIMP1 would enhance MMP activity thereby 
augmenting arterial remodeling in response to alterations in flow and promoting sprouting 
angiogenesis in response to high flow or ischemic conditions.  
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Material and Methods:  
Ethical Approval 
All animal experiments were approved by the York University Animal Care Committee 
and conducted in accordance with the Canadian Council for Animal Care Guidelines.  
Animals  
B6.129S4-Timp1tm1Pds, which harbor mutated Timp1 alleles (in-frame stop codon within 
exon 3), were purchased from Jackson Laboratories (Bar Harbor, ME, USA).  Because 
Timp1 is located on the X chromosome, the female genotype is Timp1-/- while the male 
genotype is Timp1-/0.  For simplicity, we will refer to them all as Timp1-/-.  The Timp1-/- 
genotype was confirmed by PCR analysis of DNA extracted from ear punches utilizing 
the REDExtract-N-Amp Tissue PCR kit (Sigma) and primers for the mutated upstream 
(5’GCTATCAGGACATAGCGTTGG3’) and non-mutated downstream 
(5’AACCAGGCCCTTTTCCTTTA3’) (Invitrogen, Burlington, ON) sites within exon 3 
of Timp1.  Age matched C57BL/6 mice were purchased from Charles River Laboratories 
(Sherbrooke, QC) and used as wild-type (WT) controls. Equal numbers of males and 
females aged 8 to 11 weeks were used for all experiments. Mice were housed in the York 
University Vivarium in 12 hour light-dark cycle and fed a standard chow diet ad libitum.  
Femoral Artery Ligation  
The FA ligation model was used to evoke: a) ischemia-induced remodeling within lower 
limb muscle microvessels, and b) flow-induced remodeling in response to a sustained 
increase in flow through preexisting collateral arteries.  Mice were randomly assigned to 
sham or ligation groups.  Under inhaled isoflurane anesthesia, the right FA was dissected 
away from the vein and nerve distal to the epigastric artery. The artery was ligated with 
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6-0 suture (ligation group) or remained un-ligated (sham) and incisions were closed with 
5-0 suture.  Animals were administered buprenorphine (0.15mg/10g BW), at the time of 
surgery, for pain management. Prior to surgery (Pre), immediately post-surgery (D0) and 
on days 4, 7, 14 and 21 (D4, D7, D14 or D21) post-surgery, hind-limb blood flow was 
assessed non-invasively by laser Doppler imager (PeriMed, Stockholm, Sweden) while 
animals were maintained under isoflurane anesthesia, with body temperature maintained 
at 37°C using a warming pad.  A minimum of 2 scans was captured for each animal, 
using a constant scanning area (7.5 x 3.7 cm) and working distance (21.2 cm).  Using 
PIMSoft software (PeriMed), regions of interest (ROI) were drawn to encase the knee to 
foot region in the surgery and control legs and average mean pixel intensity within each 
region was determined.  Intensities were represented as the ratio of mean pixel intensity 
of the surgical limb to the non-surgical limb. On days 14 and 21 post surgery, FA 
collateral blood flow was assessed more directly using a needle laser Doppler probe 
(mooreVMS-LDF2 laser Doppler monitor, Moor Instruments, Delaware USA) while 
animals were under isoflurane anesthesia, with body temperature maintained at 37°C 
using a warming pad.  An!incision!was!made!through!skin!to!expose!the!underlying!tissue!and!to!allow!direct!positioning!of!the!needle!probe!over!each!artery!location.!!More!specifically,!the needle probe was positioned over a collateral route, 3 vessels that 
have previously been described to bypass the FA (Hoefer, 2001).  Flow was recorded for 
one minute at each location. Subsequently, flow through each vessel was normalized 
(surgery: control) and subsequently, the flow ratios of all three vessels were averaged to 
obtain an average collateral flow ratio per animal.  
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Prazosin Treatment  
To induce a chronic increase in blood flow within the skeletal muscle microvascular 
network, mice were treated with the α1-adrenergic inhibitor prazosin (50 mg/L; P7791, 
Sigma), which was administered in the drinking water for 2, 4, 7, 14 or 21 days (Dawson 
and Hudlická, 1989; Ichioka et al., 1998).  Based on an average daily water consumption 
of 6 ml per mouse, mice ingested approximately 0.3 mg prazosin/day. Control animals 
were provided with tap water ad-libitum.  
Tissue Isolation 
Animals were anesthetized with inhaled isoflurane on day 4, 7, 14, or 21 and muscles 
were removed, weighed and snap frozen in liquid nitrogen or liquid nitrogen-cooled 
isopentane for further analysis.   
Muscle Histology  
10 to12µm thick cryosections from the belly of the EDL muscle were fixed and stained 
with fluorescein isothiocyanate-conjugated Griffonia simplicifolia isolectin B4 (1:100; 
Vector Laboratories, Burlington ON, Canada) and anti-smooth muscle actin-Cy3 (1:300; 
C6198, Sigma Aldrich, Oakville ON, Canada) as described previously (Uchida et al., 
2015). Sections were viewed using a Zeiss M200 inverted microscope with 20x objective.  
Images were captured using a cooled CCD camera controlled with MetaMorph imaging 
software. Capillary-to-fiber (C:F) counts were averaged from 3 to 4 independent fields of 
view per mouse by a blinded observer.  The number of smooth muscle actin-positive 
(SMA+) vessels was counted for each field of view and their perimeters measured using 
MetaMorph software.  Where a lumen could not be seen, perimeter was estimated by 
measuring the vessel diameter and using the formula P=2πr. Analysis of average SMA+ 
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vessels was performed on vessels 20µm and smaller as these vessels are within the range 
of newly formed arterioles.  
Electron Microscopy 
The extensor hallucis proprius (EHP) muscle of animals from the prazosin experiments 
were fixed in situ, then post-fixed and processed for transmission electron microscopy 
using standard protocols.  This muscle is thin, enabling the rapid post-fixation that is 
ideal for electron microscopy).  Ultrathin sections were viewed using a Philips EM201 
electron microscope at 20,000X magnification.  Images were taken using a cooled CCD 
digital camera (L-3, Scientific Instruments and Applications, Duluth, GA, USA). 
Protein Extraction and Matrix Metalloproteinase Activity 
Protein was extracted from TA muscle using RIPA buffer including protease inhibitors 
and phosphoSTOP (Roche, Indianapolis IN) as described previously (Milkiewicz et al., 
2011). Protein extracts were quantified using a bicinchoninic acid assay (Pierce, Fischer 
Thermoscientific). 5µg of protein per muscle was used to assess overall MMP activity 
within EDL muscle homogenates using the Amplite TM fluorimetric universal MMP 
activity assay kit (#13510; AAT Bioquest, California, USA).  
Measurements of Vascular Permeability 
A subset of Timp1-/- and WT mice at the 4 day time point post-prazosin or FA ligation 
were injected with Evans Blue dye (3% in 0.9% saline i.p, at a dose of 1 or 2ml/kg of 
body weight; E2129, Sigma: Oakville, ON, Canada), and were anesthetized after 20 
minutes for tissue extraction.  A section of liver (50 to 90mg) and both EDL and soleus 
muscles were removed, weighed and placed in formamide at 56°C overnight to extract 
the dye.   Sample absorbance at 560 nm was assessed using a microplate reader 
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(CytationTM 3, Biotek, Vermont USA and compared to a standard curve of known 
concentrations of Evans blue dye in formamide.  The amount of dye in each sample was 
calculated relative to tissue weight (ng dye/mg EDL or liver).  In the ligation study, the 
amount of dye in the EDL from the ligated leg was expressed as a ratio to that of the non-
ligated leg. In the prazosin study, the dye amount in the EDL was expressed as a ratio to 
liver.   
RNA Analysis by Real Time qPCR 
RNA was isolated from TA muscle using the Qiagen RNeasy Fibrous Tissue Mini Kit 
(74704, Qiagen, Toronto, ON Canada) as per the manufacturer’s instructions. RNA was 
reverse transcribed using MMLV reverse transcriptase (New England Biolabs, Whitby 
ON Canada). cDNA were analyzed by qPCR using TaqMan® Fast Advanced Master 
Mix (4444963; Invitrogen Canada; Burlington, ON Canada) and TaqMan® probes for 
HPRT1 (Mm00446968_m1), GAPDH (Mm004308313_m1), MMP2 
(Mm00439498_m1), TIMP1 (Mm00441818_m1), TIMP2 (Mm00441825_m1), TIMP3 
(Mm00441826_m1), TIMP4 (Mm01184417_m1), VEGFA (Mm00437306_m1), ICAM-1 
(Mn00516023_m1), VCAM (Mn01320970_m1) or eNOS (Mn00435217_m1) and 
detected using the ABI 7500 Fast PCR system (Invitrogen Canada). The comparative Ct 
(2-ΔCt) method was used to determine mRNA expression of the target genes relative to the 
housekeeping genes HPRT1 or GAPDH.  
Cell culture and shear stress stimulation 
Skeletal muscle microvascular endothelial cells were isolated from tibialis anterior 
muscle of male Sprague Dawley rats as described previously (Han et al., 2003).  Cells 
were cultured with Dulbecco’s Modified Eagle Medium (Invitrogen) supplemented with 
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10% heat denatured FBS, 1mM sodium pyruvate, 1mM Glutamax (Invitrogen), 50 units 
penicillin, 0.5mg/ml streptomycin and 1.25µg/ml fungizone (Gibco). Cells were used 
between passages 4 to 7. Shear stress experiments were conducted as previously 
described (Milkiewicz et al., 2006). Briefly, for shear stress experiments, endothelial cells 
were plated on gelatin coated glass cover slips. Cells were subjected to 5 dynes/cm2 shear 
stress for 24 hours using parallel plate flow systems (Bioptechs). This shear stress was 
utilized because it is comparable to the reported normal/resting capillary shear stress 
within skeletal muscle (Hudlicka et al., 2006).  
Statistical analysis 
Results were expressed as mean + SEM and analyzed via two-tailed students t-test, one-
way ANOVA, or a two-way ANOVA with subsequent Tukey or Bonferroni post hoc 
tests (Prism4; Graphpad software Inc; La Jolla, CA, USA). In all cases, P< 0.05 was 
considered statistically significant.   
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Results: 
Characteristics of the skeletal muscle microvascular network in Timp1-/- mice 
 Under basal conditions, the EDL microvascular network within Timp1-/- mice was 
characterized by a significantly lower C:F and reduced density of small arterioles (SMA+ 
vessels <20 µm diameter) compared to WT animals (Table 2.1).   We considered that the 
phenotype of Timp1-/- mice might exhibit sexual dimorphism, because the Timp1 gene is 
located on the X chromosome.  However, C:F and arteriole density did not differ between 
male and female mice of WT or Timp1-/- mice (Table 2.1).  Both plantaris and 
gastrocnemius were proportionately smaller in the Timp1-/- mice compared to WT mice 
of the same sex, but this influence was not detected in other muscles (Table 2.1). As no 
sex differences were evident with respect to C:F or SMA+ vessel density, male and 
females were grouped together for all subsequent analyses.  Despite the reduced number 
of microvessels, there was no evidence of apoptosis in the EDL of Timp1-/- mice, as 
assessed by cleaved caspase 3 staining (data not shown).  
Impaired microvascular remodeling within the ischemic limb of Timp1-/- mice 
The angiogenic response within chronically ischemic muscle is minimal despite 
the generation of a pro-angiogenic environment, which may be a consequence both of 
reduced shear stress signaling and an upregulation of anti-angiogenic factors (Scholz et 
al., 2002; Milkiewicz et al., 2011; Roudier et al., 2013).  A significant increase in TIMP1 
mRNA was detectable in the ischemic muscle of WT mice 4 days after FA ligation 
(Figure 2.1A), suggestive of a potential anti-angiogenic role for TIMP1.  
As expected, C:F did not increase within the ischemic muscle in response to FA 
ligation in WT mice, similar to previous reports (Scholz et al., 2002; Milkiewicz et al., 
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2011; Roudier et al., 2013). However, ischemia-induced angiogenesis did not occur in 
Timp1-/- mice (Figure 2.1B & C), despite the presence of a pro-angiogenic stimulus, as 
evident by a significant increase in VEGF-A mRNA (Figure 2.1D).  The average 
diameter of SMA+ vessels was unaffected by genotype or ischemia (data not shown).  
The density of small arterioles was significantly reduced in Timp1-/- mice, but was 
unaffected by ischemia (Figure 2.1E).  These findings suggest that endogenous TIMP1 
does not act to restrain angiogenesis or arteriolar remodeling within the ischemic muscle. 
Effects of ischemia and Timp1-/- on TIMP and MMP expression  
To further explore the mechanism(s) mediating the lack of alteration in vascular 
remodeling in Timp1-/- mice, the expression of MMPs and the other TIMPs was 
examined.  TIMP1 deletion did not influence the basal expression of MMP2 or MMP9 
(Figure 2.2A & B). MMP2, but not MMP9, mRNA was significantly increased within the 
ischemic skeletal muscle of both WT and Timp1-/- mice (Figure 2.2A & B).  TIMP2, 3 
and 4 were increased significantly in Timp1-/- vs. WT mice under ligation and basal 
conditions (Figure 2.2C- E).  Microvascular permeability of the EDL, as assessed by 
extravasation of Evans blue dye, was examined as a potential downstream effect of 
excess proteolysis. Basal permeability was unaffected by the loss of TIMP1, but 
permeability increased within the ischemic EDL muscle of Timp1-/- mice (Figure 2.2F).  
Global MMP activity was not altered in Timp1-/- compared to WT mice (Figure 2.2G). 
Together, these data suggest that MMP activity is maintained by compensatory increases 
in other TIMPs and that the augmented vascular permeability within the ischemic muscle 
of Timp1-/- mice may be a consequence of other structural alterations to the 
microvasculature.  
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Because changes in gene expression within ischemic muscle are impacted by mild 
hypoxia/metabolic stress as well as reduced flow, we also examined cultured 
microvascular endothelial cells maintained under normal flow or no flow conditions.  
TIMP1 mRNA was substantially lower under no-flow (~ 0 dynes/cm2) compared to 
normal flow conditions (~5 dynes/cm2) (Figure 2.3A). Conversely, mRNA levels of 
TIMP3 and MMP2 did not differ between normal and no-flow conditions (Figure 2.3B & 
C respectively).  Thus, the reduction of blood flow within ischemic muscle may act to 
down-regulate endothelial TIMP1 expression within endothelial cells, but this appears to 
be counter-balanced by the hypoxic/metabolic stress, resulting in an overall increase in 
TIMP1 expression within the ischemic microenvironment. 
Timp1-/- mice exhibit impaired blood flow recovery post-ligation  
The FA ligation model also was used to examine the role of TIMP1 in flow-
induced collateral artery remodeling.  FA ligation causes diversion of blood flow through 
smaller collateral pathways, which induces outward remodeling of the collateral arteries 
(Cai et al., 2004).  Collateral dependent recovery of hind-limb blood flow, as assessed by 
laser Doppler imaging, was restored to pre-ligation values by day 14 in WT mice (Figure 
2.4A). However, blood flow in the ligated limb of Timp1-/- mice remained significantly 
lower than that of the non-ligated limb even after 21 days of recovery (Figure 2.4A &B). 
Similarly, collateral vessel blood flow, as assessed by Doppler needle probe, increased 
significantly in WT but not Timp1-/- mice after 14 days of recovery (Figure 2.4C).  After 
both 14 and 21 days post-ligation, average collateral blood flow was greater in WT than 
Timp1-/- mice (Figure 2.4C). These findings suggest an impaired collateral artery 
remodeling response within Timp1-/- mice.   
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Timp1-/- mice have reduced microvascular remodeling with prazosin treatment 
We utilized chronic prazosin treatment to further evaluate microvascular 
remodeling in Timp1-/- mice in response to elevated flow.  Previously, we reported that 
high shear stress (15 dynes/cm2) reduced MMP2 and increased TIMP1 expression 
(Milkiewicz et al., 2006; Uchida and Haas, 2014), suggesting a role for TIMP1 in 
promoting splitting rather than sprouting angiogenesis. C:F increased in WT mice after 
21 days of prazosin treatment, but not in the Timp1-/- animals, whose C:F ratio was 
significantly lower than WT animals at every time point (Figure 2.5A & B). SMA+ vessel 
density was increased significantly in WT mice after 7 days of prazosin treatment, but 
was significantly lower in Timp1-/- mice at all time points (Figure 2.5C).   
Examination of capillary ultrastructure by electron microscopy revealed activation 
of endothelial cells in response to 7 and 14 days of prazosin treatment in WT mice only. 
This was evidenced by membrane ruffling and protrusions of the endothelial cells into the 
capillary lumen (Figure 2.6A, indicated by arrows).  However, these indicators of 
endothelial cell activation were not observed in the Timp1-/- mice at any time point 
(Figure 2.6A).  Luminal protrusions consistent with splitting angiogenesis were detected 
in WT mice only.  Abluminal protrusions were not detected in capillaries from WT or 
Timp1-/- mice.   
VEGF-A and nitric oxide are critical mediators of flow induced angiogenesis 
(Williams et al., 2006). Thus, we postulated that the impaired remodeling responses in 
Timp1-/- mice may be caused by reduced expression of VEGF-A or eNOS.  However, the 
prazosin induced increases in VEGF-A and eNOS mRNA were not different between WT 
and Timp1-/- mice (Figure 2.6B & C respectively). 
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Prazosin increases microvascular permeability in Timp1-/- mice 
Electron microscopy images also showed evidence of cells within the vascular 
compartment that were adherent to, or in the process of migrating through, the capillary 
wall in muscles from Timp1-/- mice (Figure 2.7A).  This phenomenon was not detected in 
any of the samples from WT mice. These images suggested alterations in vascular 
permeability and/or a potential increase in inflammation within Timp1-/- mice. VCAM-1 
and ICAM-1 mRNA, two endothelial pro-inflammatory adhesion molecules (Jublanc et 
al., 2011), were assessed. No significant differences were noted in VCAM-1 expression 
(Figure 2.7B). ICAM-1 mRNA expression was significantly increased by prazosin 
treatment in the Timp1-/- mice (Figure 2.7C). Evans Blue dye extravasation indicated a 
significant increase in permeability after 4 days of prazosin treatment in the EDL muscles 
Timp1-/- but not in WT mice (Figure 2.7D).  A similar influence on permeability also was 
detected in the oxidative soleus muscles of 4 day prazosin-treated Timp1-/- mice 
compared to their time matched WT controls (0.77 ± 0.05 vs. 0.50 ± 0.05 ng/mg muscle, 
respectively; P<0.05).  However, the augmentation in permeability was not associated 
with increased MMP activity, as there was no influence of Timp1-/- on global MMP 
activity (Figure 2.7E).   
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Table 2.1: Baseline animal characteristics of WT and Timp1-/- mice.  
 
 WT Timp1-/- 
 Male 
(n=12) 
Female 
(n=24) 
Male 
(n=23) 
Female 
(n=25) 
Body mass (g) a,c 24.1±0.60 19.2±0.20 26.9±0.60b 21.1±0.40b 
Soleus mass (g) c 8.7±0.30     7.1±0.20 9.1±0.20 7.6±0.10 
Soleus mass:body mass ns 0.36±0.01 0.36±0.01 0.34±0.01 0.35±0.01 
Plantaris mass (g) c 16.8±0.50 12.1±0.20 17.2±0.50 12.8±0.40 
Plantaris mass:body mass d 0.70±0.01 0.63±0.01 0.64±0.01e 0.61±0.02 
Gastrocnemius (g) c 119.7±2.1 88.3±1.2 119.5±3.20 88.6±1.90 
Gastrocnemius mass:body 
mass d 
5.0±0.08 4.6±0.04 4.4±0.07e 4.2±0.08e 
TA (g) c 44.6±0.70 35.2±0.50 48.5±1.30 38.3±0.80 
TA mass:body mass ns 1.9±0.03 1.8±0.01 1.8±0.04 1.8±0.04 
EDL mass (g) c 11.3±0.20 8.4±0.20 11.8±0.40 8.9±0.20 
EDL mass:body mass ns 0.47±0.01 0.44±0.01 0.44±0.01 0.43±0.01 
EDL capillary-to-fiber ratio a 1.4±0.04 1.3±0.2 1.0±0.04e 1.0±0.05f 
EDL SMA+ vessel density 
(#/mm2) g 
22.7±1.10 23.7±1.60 11.9±1.20h 14.3±1.90 
 
All data are presented as means ± standard error of measurement 
a, 2 way ANOVA genotype effect, P<0.0001 
b, post hoc significant difference compared to respective WT gender matched group, 
P<0.01  
c, 2 way ANOVA gender effect P<0.0001  
d, 2 way ANOVA genotype and gender effects,  P<0.01 and P<0.001, respectively 
e, post hoc significant difference compared respective WT of same sex, P<0.0001 
f, post hoc significant difference compared respective WT of same sex, P<0.05 
g, 2 way ANOVA genotype effect, P<0.01 
h, post hoc significant difference compared respective WT of same sex, P<0.01 
ns, non significant 
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Discussion:  
This study demonstrated that the loss of TIMP1 was associated with a constitutive 
reduction in the skeletal muscle microvascular network, as evidenced by a lower C:F 
ratio and reduced density of small SMA+ vessels. Vascular remodeling in response to 
alterations in blood flow was impaired by the loss of TIMP1. The loss of TIMP1 did not 
elicit an angiogenic response to hind-limb ischemia. Furthermore, in response to hind-
limb ischemia, collateral artery flow and whole limb blood flow recovery were blunted 
by the deletion of TIMP1.  Angiogenesis and arteriolar remodeling in response to 
prazosin induced increases in flow were also abrogated in Timp1-/- mice, despite increases 
in VEGF-A and eNOS mRNA equivalent to those of WT mice.  
The reduction in skeletal muscle microvascular content in untreated Timp1-/- mice 
suggests that TIMP1 plays an unexpected and previously unreported role in establishing a 
mature microvascular network.  This effect was sex independent.  Furthermore, it should 
be noted that TIMP1 does not play a critical role in early vascular development as  
Timp1-/- pups are viable and mature Timp1-/- mice are fertile. Considering that maturation, 
branching and pruning of the microvascular network itself is highly dependent on blood 
flow (Lenard et al., 2015), it is possible that the reductions in C:F and arteriole density in 
Timp1-/- mice under resting conditions reflects a generalized failure of appropriate flow-
mediated remodeling processes.  
The influence of Timp1-/- on vascular remodeling was assessed using FA ligation 
and prazosin treatment as experimental tools to manipulate oxygen levels and blood flow 
through the skeletal muscle circulation.  In contrast to the initial hypothesis that loss of 
 68!
TIMP1 would enhance remodeling, we observed a failure to undergo adaptive 
angiogenesis and arteriogenesis in Timp1-/- mice.  
The microvascular response to low oxygen and low blood flow was examined in 
vivo via FA ligation. Hypoxia is a potent stimulus for increased VEGF production 
(Shweiki et al., 1992). However, the increase in VEGF-A does not result in angiogenesis 
within ischemic muscle (Scholz et al., 2002; Milkiewicz et al., 2011; Roudier et al., 
2013). The increase in TIMP1 within ischemic muscle suggested that it might restrain 
sprouting angiogenesis due to inhibition of MMP activity.  However, TIMP1 deletion did 
not elicit ischemia induced angiogenesis. Neither the basal or stimulus induced level of 
VEGF-A or MMP expression was altered within muscles of Timp1-/- mice. Thus, the loss 
of TIMP1 is unable to alter the microenvironment to allow for ischemia induced vascular 
remodeling to occur.  
Vascular remodeling in response to elevated blood flow was not detected within 
the collateral zone generated by FA ligation of Timp1-/- mice, based on analysis of hind 
limb blood flow recovery and collateral artery flow.  Likewise, shear stress induced 
angiogenesis and arteriogenesis did not occur within the skeletal muscle microvasculature 
of Timp1-/- mice following prazosin administration.  Both eNOS and VEGF-A play 
critical roles in flow induced angiogenesis and arteriogenesis (Rudic et al. 1998; 
Hudlicka et al. 2006; Williams et al. 2006).  However, neither basal levels nor flow 
induced increases in VEGF-A or eNOS mRNA were altered in Timp1-/- mice, indicating 
that the signal pathways that control the expression of these important factors are not 
disrupted by TIMP1 deletion.  Nonetheless, the lack of prazosin-induced endothelial cell 
activation and luminal protrusions within capillaries of Timp1-/- mice suggests that the 
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loss of TIMP1 impairs downstream cellular processes associated with flow induced 
angiogenesis and arteriogenesis.  
Previously, shear induced expression of TIMP1 was postulated to limit 
proteolysis and to prevent abluminal sprouting (Milkiewicz et al., 2008; Uchida and 
Haas, 2014), thus implying that deletion of TIMP1 would provoke an abluminal 
sprouting response to elevated flow. However, there was no evidence of abluminal 
sprouting in capillaries of prazosin-treated Timp1-/- mice. Furthermore, we did not find 
evidence of augmented MMP activity within skeletal muscle of Timp1-/- mice under any 
conditions.  The compensatory increases in TIMP2, 3 and 4 mRNA observed in the 
current study may explain the lack of increase in overall MMP activity, as they may have 
prevented excessive proteolysis and minimized increases in vascular permeability.  
Similar compensatory increases in TIMP2 (Ikonomidis et al., 2005) and TIMP3 (Kim et 
al., 2001) have been detected within cardiac muscle and kidney tissue of Timp1-/- mice.   
Timp1-/- mice exhibited increased vascular permeability under ‘stress’ conditions 
(ischemia or elevated flow), indicating a failure to maintain vascular integrity.  Capillary 
permeability is strictly maintained by adherens and tight junctions (Dejana, 2004).  While 
increased capillary permeability may occur as a consequence of increased MMP-
mediated cleavage of junctional proteins (Alexander and Elrod, 2002), we do not have 
evidence that this occurred in Timp1-/- mice.  However, we cannot exclude the possibility 
of localized peri-capillary increases in proteolysis that were not detectable by the analysis 
of whole muscle global MMP activity. Excessive permeability also occurs as a 
consequence of inflammation (Cotran and Majno, 1964; Chistiakov et al., 2015).  Timp1-
/- (but not Timp2-/-) mice were previously reported to have increased vascular permeability 
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and inflammation within the lung (Kim et al., 2005).  In the current study, ICAM1 
mRNA was significantly elevated in Timp1-/- mice in response to prazosin treatment.  The 
increase in ICAM1 may contribute to the increased membrane permeability and cellular 
infiltration within Timp1-/- capillaries, as it has been reported that ICAM1 activation 
induces intracellular signals that result in enhanced endothelial solute permeability 
(Sumagin et al., 2011).   
The phenotype of Timp1-/- and concurrent lack of alteration in MMP activity 
raises the possibility that TIMP1 impacts the vasculature in an MMP-independent 
mechanism. It has been reported that TIMP1 exerts MMP-independent functions that 
influence cell survival and proliferation (reviewed in, Ries 2014); however, these studies 
were conducted on myeloid and epithelial cells rather than endothelial cells. Our 
laboratory found that recombinant TIMP1 did not impact survival of cultured endothelial 
cells (Mandel et al., 2013). This, together with a lack of detectable apoptosis in Timp1-/- 
muscle in the current study, suggests that TIMP1 deletion does not impact endothelial 
cell survival.  
The current study demonstrates that TIMP1 plays an important role in the 
maturation and expansion of the skeletal muscle microvascular network.  While TIMP1 
does not act to constrain ischemia induced angiogenesis, our study indicates that it is 
required for appropriate flow induced angiogenesis and arteriogenesis.  The cellular 
actions of TIMP1 that result in the impaired vascular remodeling responses exhibited by 
Timp1-/- mice remain to be identified.  While there was no evident increase in MMP 
activity in Timp1-/- mice, the increased vascular permeability observed in response to 
prazosin or ischemia is indicative of a failure to maintain vascular integrity.  This study 
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demonstrates that TIMP1 does not act as an anti-angiogenic factor within the skeletal 
muscle microvasculature, providing evidence of a critical permissive function of TIMP1 
in the processes associated with flow induced vascular remodeling.  
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Chapter Summary: 
Glucocorticoids (GC) are angiostatic and elicit capillary rarefaction within skeletal 
muscle, which can subsequently impair blood distribution and muscle function. 
Conversely, skeletal muscle angiogenesis can be induced by treatment with the alpha-1 
adrenergic receptor inhibitor prazosin due to augmented skeletal muscle blood flow. We 
hypothesized that corticosterone (CORT) treatment would inhibit endothelial mediated 
shear stress signaling and subsequently the angiogenic response to prazosin 
administration. CORT pellets were implanted subcutaneously (400 mg/rat) for 1 or 2 
weeks in male Sprague Dawley rats, with or without concurrent prazosin treatment 
(50mg/L in drinking water).  The CORT-induced reduction in capillary-to-fiber ratio 
(C:F) corresponds with reduced Angiopoietin-1 mRNA. Rarefaction was prevented with 
concurrent prazosin administration; however, no angiogenesis or arteriogenesis occurred 
in CORT-treated animals.  The shear induced increase in pSer473 Akt was impaired by 
2W CORT treatment. In 2W CORT animals, VEGF-A protein was increased 
significantly by concurrent prazosin treatment.  However, prazosin did not rescue CORT-
induced reductions in TGFβ or MMP2 mRNA. Shear stress dependent signaling was 
assessed in cultured rat skeletal muscle endothelial cells pre-treated with CORT (600nM) 
for 48 hours, then exposed to 15 dynes/cm2 shear stress or maintained with no flow. 
CORT blunted the shear stress induced increases in pSer473 Akt, VEGF and 
TGFβ mRNA, while MAPK phosphorylation or nitric oxide (NO) production were 
unaffected. This study demonstrates that the maintenance of MAPK, NO and VEGF 
responsiveness to augmented shear stress contributes to the prevention of CORT-
mediated rarefaction, but is unable to elicit an angiogenic or arteriogenic responses.  
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Introduction: 
Endothelial cells are continuously exposed to the physical force of blood flow, 
which generates shear stress. Shear stress activates a diverse array of intracellular 
signaling networks within endothelial cells predominantly those involved in promoting 
cell survival and maintenance of a healthy vasculature (Sessa, 2004). Shear stress 
activates endothelial nitric oxide synthase (eNOS), increasing nitric oxide (NO) 
production (Kuchan and Frangos, 1994), along with vascular endothelial growth factor 
(VEGF) (Milkiewicz et al., 2001). Both NO and VEGF-A are imperative for survival and 
angiogenic signaling (Williams et al. 2006; Williams et al. 2006b). Animal models have 
demonstrated that sustained increases in shear stress within the skeletal muscle capillary 
network stimulates angiogenesis via luminal splitting (Ziada et al., 1989; Zhou et al., 
1998; Gee et al., 2010). Shear stress stimulates VEGF-A production by both endothelial 
cells and the surrounding skeletal myocytes, which is essential for shear stress induced 
angiogenesis (Milkiewicz et al. 2001; Williams et al. 2006; Gee et al. 2010; Uchida et al. 
2015).  Conversely, shear stress has been reported to repress production of the anti-
angiogenic matrix protein thrombospondin-1 (TSP-1) (Bongrazio et al., 2008).  
Furthermore, augmented shear stress is a potent stimulus for arteriogenesis or the 
outward remodeling of arteries and/or arterioles (Skalak, 2005; Cai and Schaper, 2008).  
Arteriogenesis will result in more large vessels thereby normalizing the augmented shear 
response and reducing the angiogenic stimulus (Schaper, 2009).  
Elevated levels of glucocorticoids (GC) are observed in individuals with poorly 
controlled diabetes, metabolic syndrome, or Cushing syndrome (Lansang and Hustak, 
2011; Beaudry and Riddell, 2012). The prolonged pathophysiological increase in GC 
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causes the loss (rarefaction) of preexisting capillaries within skeletal muscle (Shikatani et 
al., 2012).  Loss of skeletal muscle capillaries is associated with poor skeletal muscle, 
metabolic and cardiovascular health (Nascimento et al., 2013; Triantafyllou et al., 2015), 
likely due to reduced access to hormones and nutrients such as insulin and glucose 
(Bonner et al., 2013). The mechanisms through which GC excess elicits the loss of 
skeletal muscle capillaries have not been established.  Research utilizing cultured cells 
has suggested that GC can exert an anti-angiogenic influence through inhibiting 
endothelial cell proliferation, matrix proteolysis, sprouting and migration (Folkman et al., 
1983; Small et al., 2005; Shikatani et al., 2012); however, evidence is lacking regarding a 
direct influence of GCs on endothelial cell apoptosis. GC excess has been reported to 
reduce the production of VEGF (Ullian, 1999; Shikatani et al., 2012) and inhibit eNOS-
dependent production of NO (Ullian, 1999). These influences suggest that GC may 
impair physiological shear stress signaling, which could impair survival signaling and 
flow-induced vascular remodeling.  
The effects of sustained increases in microvascular blood flow can be modeled 
within skeletal muscle by the administration of prazosin, an alpha-1 (α1) adrenergic 
receptor antagonist. A significant increase in skeletal muscle capillary-to-fiber ratio 
(C:F), indicative of an angiogenic response, is detectable after 7 to 14 days of prazosin 
treatment (Ziada et al., 1989; Zhou et al., 1998; Rivilis et al., 2002). Thus, in the current 
study, we utilized the model of sustained prazosin treatment and shear stress stimulation 
of cultured endothelial cells to test the hypothesis that elevated levels of CORT would 
inhibit shear stress signaling and restrain the angiogenic response to prazosin 
administration.  
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Materials and Methods: 
All animal experiments were approved by York University Animal Care Committee 
(approval number 2013-5) and conducted in accordance with the Canadian Council for 
Animal Care Guidelines. 
Animal Protocol 
Male Sprague Dawley rats (N=48; initial weight 200-250g) were purchased from Charles 
River Laboratories (Montreal, QC, Canada). Rats were housed in the York University 
Vivarium in a12 hour light-dark cycle. After 7 days acclimation, animals were assigned 
randomly to one of four groups: corticosterone-treated or wax-treated (control), with 
either regular drinking water (CORT-water and control-water), or drinking water 
containing prazosin hydrochloride (50 mg/L; P7791, Sigma Aldrich Canada) (CORT-
prazosin and control-prazosin).  All animals were fed a standard rodent chow diet (14% 
fat, 54% carbohydrate, 32% fat; 3.0 calories/g) ad libitum.  
100mg wax or CORT pellets were made and on Day 0, four pellets were implanted 
subcutaneously in the mid-scapular region of each rat, under isoflurane anesthesia, as 
described previously (Shpilberg et al., 2012). Subsequently, rodents recovered in 
individual cages and were given ampicillin (20mg/Kg body weight) in their drinking 
water.  On day 2, rats were continued with regular water or commenced with prazosin-
treated water for 7 or 14 days.  These groups will be referred to as 1W and 2W control or 
CORT- water or -prazosin.   
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Plasma Corticosterone Analysis 
Blood was collected via saphenous vein puncture at 8am on days 0, 7 and 14.  Plasma 
CORT was measured by radio-immunoassay (07-120102, MP Biomedicals; Solon, OH) 
according to manufacturer’s instructions.  
Tissue Isolation 
At the end point of each study, animals were anesthetized with inhaled isoflurane muscles 
were removed, weighed and snap frozen in liquid nitrogen or liquid nitrogen-cooled 
isopentane for further analysis, and animals were euthanized by exsanguination. 
Cell culture and shear stress stimulation 
Skeletal muscle microvascular endothelial cells were isolated from the extensor 
digitorum longus (EDL) muscle of male Sprague Dawley rats as described previously 
(Han et al., 2003).  Cells were cultured with Dulbecco’s Modified Eagle Medium 
(Invitrogen) supplemented with 10% heat denatured FBS, 1mM sodium pyruvate, 1mM 
Glutamax (Invitrogen), 50 units penicillin, 0.5mg/ml streptomycin and 1.25µg/ml 
fungizone. Cells were used for experiments between passages 4 to 7. Endothelial cells 
were plated on 35mm dishes or gelatin coated glass cover slips and pretreated with 600 
nM CORT for 48 hours, a dose that previously was shown to inhibit angiogenic behavior 
(Small et al., 2005; Shikatani et al., 2012). Shear stress experiments were conducted as 
previously described (Milkiewicz et al., 2006). Briefly, cells were subjected to 15 
dynes/cm2 shear stress for 2 hours using a parallel plate flow system (Bioptechs), to 
provide a stimulus comparable to reported capillary shear stress within skeletal muscle of 
prazosin-treated rats (Milkiewicz et al., 2001).     
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Protein Extraction and Analysis via Western Blotting or ELISA 
For western blots, protein was extracted from the tibialis anterior (TA) muscle or 
cultured endothelial cells in RIPA buffer including protease inhibitors and phosphoSTOP 
(Roche, Indianapolis IN).  Muscle extracts were processed using a tissue lyser (MM400, 
Retsch GmbH, Haan, Germany).  Protein extracts were quantified by bicinchoic acid 
assay (Pierce, Fisher Thermoscientific).  20 to 40 µg of total proteins were separated 
through 8% or 10% SDS-polyacrylamide gels under reducing conditions.  Proteins were 
transferred to PVDF membrane (Immobilon-P, Millipore) using wet transfer (Biorad 
trans-blot) and membranes were blocked for 1hr with 5% milk in TBS- 0.05% Tween 
(TTBS). Membranes were incubated overnight at 4°C with antibodies for phospho Akt 
Ser473, Thr308 (#4058 & 9275, Cell Signaling), phospho ERK1/2 (# 9101, Cell 
Signaling), phospho-p38 (#9211, Cell Signaling) or TSP-1 (#MA5-13398, Thermo 
Scientific) in 5% BSA -TTBS. Secondary antibodies (rabbit IgG-HRP) were detected by 
enhanced chemiluminescence (Pierce WestPico, Fisher Thermoscientific). Membranes 
were stripped and re-probed for total AKT (# 9272, Cell Signaling), total p38 (#9272, 
Cell Signaling) or anti-β-actin (1:5000, Santa Cruz Biotechnology, Santa Cruz CA) for 
normalization.  Blots were quantified and analyzed using Carestream software.  
For the VEGF-A ELISA, gastrocnemius muscle was solubilized in PBS and processed by 
tissue lyser. On the same day, 100µg of protein per sample was assayed by ELISA (R&D 
systems, #RRV00), as per the manufacturer’s instructions.  
RNA extraction and Real Time qPCR 
RNA was isolated from TA muscle using the Qiagen RNeasy Fibrous Tissue Mini Kit 
(74704, Qiagen, Toronto, ON Canada) as per the manufacturer’s instructions. RNA was 
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reverse transcribed using MMLV reverse transcriptase (New England Biolabs, Whitby 
ON Canada). cDNA were analyzed by Taqman qPCR using qPCR mastermix (#4444963; 
Invitrogen Canada) and Taqman probes for rat HPRT (Rn01527840), VEGF-A ( 
Rn00582935), TSP-1 (Rn01513693), Ang1 (Rn01504818), MMP2 (Mm00439498), 
TIMP1 (Rn00587558)  and TGFβ1 (Rn99999016) using the ABI 7500 Fast PCR system 
(Invitrogen Canada). For each sample, the comparative Ct method (2-ΔCt) was used to 
determine relative mRNA expression of target genes compared to the housekeeping gene 
HPRT.  
Muscle Histology and cell staining 
10µm cryosections of TA muscle were fixed with 3.7% paraformaldehyde and stained 
with fluorescein isothiocyanate-conjugated Griffonia simplicifolia isolectin B4 (1:100; 
Vector Laboratories, Burlington ON, Canada) and anti-smooth muscle actin-Cy3 (1:300; 
C6198, Sigma Aldrich, Oakville ON, Canada). Sections were viewed using a Zeiss M200 
inverted microscope with 20x objective and images were captured using a cooled CCD 
camera using Metamorph imaging software. C:F counts were averaged from 3 to 4 
independent fields of view per rat by a blinded observer. The density and diameters of 
smooth muscle actin (SMA) positive vessels were calculated.  
Statistical Analysis 
Results were expressed as mean ± SEM and analyzed by one-way or two-way ANOVA 
with subsequent Bonferroni post hoc tests where appropriate (Prism4; Graphpad software 
Inc; La Jolla, CA, USA). P < 0.05 was considered statistically significant.  
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Results:  
Plasma CORT was significantly elevated above control after both 1W and 2W of 
exogenous CORT pellet treatment, but was unaffected by prazosin administration (Table 
3.1). For complete animal characteristics see Supplementary Table 3.1.  
CORT-induced reduction in skeletal muscle capillarization is abrogated with prazosin 
treatment 
 Both 1W and 2W CORT significantly reduced skeletal muscle C:F as compared 
to time-matched control animals (Figure 3.1A-C).  C:F was elevated in 2W con-prazosin 
treated animals (Figure 3.1A & C), consistent with previous literature (Ziada et al., 1989; 
Zhou et al., 1998; Milkiewicz et al., 2007). The CORT-dependent reduction in C:F was 
prevented by 2 weeks of concurrent prazosin treatment; nonetheless, C:F remained 
significantly lower in muscles of CORT-prazosin compared to control-prazosin rats  
(Figure 3.1A & C).  
Factors associated with Corticosterone-mediated capillary rarefaction 
 We assessed factors associated with endothelial cell survival and angiogenesis to 
delineate potential mediators of CORT-induced capillary rarefaction, and the preventative 
influence of prazosin. The mRNA level of Angiopoietin-1 (Ang-1) was assessed due to 
its established role as a vascular stabilization and cell survival factor (Asahara et al., 
1998; Fukuhara et al., 2010).  Ang-1 mRNA was not altered in cultured endothelial cells 
exposed to 48 hours of elevated CORT (Figure 3.2A).  However, Ang-1 mRNA in whole 
muscle lysates was significantly decreased after both 1 and 2 weeks of CORT treatment 
(Figure 3.2B & C).  Prazosin diminished the impact of CORT treatment, as Ang-1 levels 
in 2W prazosin-treated CORT rats were no longer different from control levels (Figure 
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3.2C).  Akt is important for cell survival (Manning and Cantley, 2007) and is a 
downstream effector of Ang-1/Tie2 signaling (Daly et al., 2006).  However, 1W CORT 
did not significantly alter basal phosphorylation of Akt at Ser473 or Thr308 (Figure 3.2D 
& E). Of note, the prazosin-induced increase in pAkt Ser473 seen in wax animals was 
absent in CORT-treated animals (Figure 3.2D). No changes in Akt phosphorylation 
(Ser473 or Thr308) were detectable in the 2W treated muscles (data not shown). 
VEGF-A acts as a pro-survival as well as pro-angiogenic factor (Zachary, 2003).  
However, neither 1W or 2W CORT treatment reduced VEGF-A mRNA (Figure 3.3A & 
B). VEGF-A mRNA levels increased significantly in the 2W CORT-prazosin compared 
with CORT-water muscles (Figure 3.3B). Similarly, VEGF-A protein was significantly 
elevated at the 2W time point in CORT-prazosin compared to CORT-water treated rats 
(P<0.05, Figure 3C). 
TSP-1 can induce endothelial cell apoptosis and prevent angiogenesis (Iruela-
Arispe et al., 1999; Zhang and Lawler, 2007), and thus could contribute to CORT-
induced capillary rarefaction.   However, TSP-1 mRNA was not altered by 1W or 2W of 
CORT-treatment or by prazosin treatment (Figure 3.3D, E).  2W of CORT treatment 
elicited a small reduction in TSP-1 protein level, with no effect of concurrent prazosin 
treatment (Figure 3.3F).  Taken together, our results indicate that the alteration in Ang-1, 
rather than VEGF-A or TSP-1, may best explain the CORT-induced capillary rarefaction.  
However, the increase in VEGF-A in CORT-prazosin muscles may contribute to the 
prevention of rarefaction. 
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Prazosin-induced arteriolar remodeling is impaired in skeletal muscle of CORT-treated 
rats 
Prazosin also induces arteriolar remodeling (Skalak, 2005), analogous to the 
outward remodeling that occurs in larger arteries exposed to elevated shear stress (Pipp, 
2004). While SMA+ blood vessel density was unaltered by 2 weeks of prazosin or CORT 
treatment (Figure 3.4A), SMA+ vessel diameter was augmented by prazosin-treatment 
within control animals only (Figure 3.4B). Shear stress stimulated outward remodeling of 
blood vessels can be promoted by TGFβ1 signaling (van Royen et al., 2002) and MMP 
activity (Haas et al., 2007). 1W CORT treatment significantly blunted the level of TGFβ1 
mRNA; however, this influence was not detected after 2 weeks of treatment (Figure 3.4C 
& D). We previously reported that CORT treatment repressed MMP2 expression in 
cultured endothelial cells (Shikatani et al., 2012). In the current experiment, we observed 
that MMP2 mRNA was reduced significantly within the skeletal muscle of CORT treated 
rats and was not affected by concomitant prazosin treatment (Figure 3.4E). TIMP1 
mRNA, an endogenous inhibitor of MMP proteolytic activity, was not altered by CORT 
or prazosin in 2W treated animals (Figure 3.4F).  Thus, the repression of TGFβ1 and 
MMP2 with CORT treatment is consistent with the impaired arteriolar remodeling in 
response to increased blood flow. 
CORT-dependent regulation of pro-survival and angiogenic factors in endothelial cells 
Due to the impairment of normal blood flow remodeling responses in CORT-
treated animals, we used cultured endothelial cells to more specifically assess the 
influence of CORT on endothelial cell shear stress dependent signaling. Shear stress 
stimulates endothelial cell phosphorylation of ERK1/2 and p38 MAPK (Gee et al., 2010) 
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and Akt (Dimmeler et al., 1998). CORT did not attenuate the shear stress stimulated 
phosphorylation of ERK1/2 or p38 MAPK (Figure 3.5A & B).  Interestingly, CORT 
treatment abolished the shear stress mediated phosphorylation of Akt at Ser473 while 
phosphorylation at Thr308 was unaffected (Figure 3.5C & D).  The shear stress induced 
increase in nitrite levels, a measure of NO production, was not altered by CORT (Figure 
3.5E). Elevated shear stress significantly increased VEGF-A mRNA in untreated cells, 
but this effect was blunted in CORT-treated cells (Figure 3.5F). TSP-1 mRNA level was 
not influenced by shear stress nor CORT treatment of endothelial cells (Figure 3.5G). 
TGFβ1 mRNA was significantly reduced by CORT-treatment; however, the shear stress 
induced increase in TGFβ1 expression was maintained in CORT-treated cells (Figure 
3.5H). 
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Table 3.1: Animal plasma CORT concentration 
 
 1 Week 
Plasma corticosterone 
(ng/ml) Control-Water (n=5) 
Control-
Prazosin 
(n=5) 
CORT-Water  
(n=5) 
CORT-Prazosin 
(n=5) 
17.54±1.4 18.94±5.5 583.1±39.8# 485.5±72.3# 
 2 Weeks 
Plasma corticosterone 
(ng/ml) 
Control-Water 
(n=5) 
Control-
Prazosin 
(n=5) 
CORT-Water  
(n=9) 
CORT-Prazosin 
(n=6) 
16.21± 6.5 9.6 ±0.6 296.3±34.4# 284.7±34.2# 
Values are expressed as mean ± standard error 
#, Significant difference compared to respective control group, as determined by two-way 
ANOVA and Bonferroni post hoc analysis. 
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Figure 3.5: Influence of corticosterone on endothelial specific shear stress 
responsiveness 
 
Cultured rat skeletal muscle endothelial cells were pre-treated with CORT (600 nM) for 
48 hours prior to shear stress (15dynes/cm2), or were maintained in static conditions (C) 
for 2 hours.  A-D: Whole cell lysates were analyzed by Western blotting. A) Phospho 
ERK1,2 protein level relative to b-actin. B) Phospho p38 protein level relative to total 
p38. C) Phospho-Ser473 Akt protein level relative to total Akt. D) Phospho-Thr308 Akt 
protein level relative to total Akt. 
Two-way ANOVA indicated a significant shear effect for all kinases (pERK1,2- 
P=0.007; pp38- P=0.02; pSerAkt- P=0.02; pThrAkt- P=0.0003n=3-4). *, ** P<0.05, 
P<0.01 compared to respective static control, post hoc analysis.  A significant interaction 
between shear stress and CORT was detected only for pAktSer473 (# P=0.05, n=3-4).  
E) Nitric oxide level was assessed indirectly by Griess assay. A main effect of shear 
stress was detected (P=0.0006; n=6).  (*,**P<0.05 and P<0.01, relative to static controls 
as assessed via post hoc analysis). mRNA was isolated from skeletal muscle endothelial 
cells that were pre-treated for 48 hours with Cort (600nM) prior to 2 hr of elevated shear 
stress (15 dynes/cm2). mRNA was quantified by Taqman qPCR and expressed as 2-
DCt.  VEGF-A (F), TSP-1 (G) and TGF-b (H) mRNA levels were assessed relative to the 
housekeeping gene hypoxanthine-guanine phosphoribosyltransferase-1 (HPRT1). F) Two 
way ANOVA and post hoc test revealed a significant shear effect in control cells on 
VEGF-A mRNA expression (*P <0.05 compared to respective control group, n=6). G) 
No significant alterations were found in TSP-1 mRNA expression. H) There was an 
overall CORT and prazosin effect (* & # P<0.05 respectively) on TGF-b mRNA 
expression (n=4-6).  
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Supplementary Table 3.1: Body composition and plasma CORT levels of Control and 
CORT treated animals  
 
 1 Week 
 Control-Water 
(n=5) 
Control-
Prazosin (n=5) 
CORT-Water  
(n=5) 
CORT-Prazosin 
(n=5) 
Plasma corticosterone 
(ng/ml) 17.54±1.4 18.94±5.5 583.1±39.8
# 485.5±72.3# 
Body weight  
(kg) 0.36±0.01 0.36±0.008 0.26±0.006
# 0.25±0.002# 
TA relative weight 
(g/kg BW) 1.77±0.06 1.85±0.04 1.71±0.05 1.71±0.08 
EDL relative weight  
(g/kg BW) 0.5±0.02 0.52±0.01 0.52±0.02 0.51±0.01 
Plantaris relative weight 
(g/kg BW) 0.87±0.75 0.93±0.04 0.84±0.04 0.87±0.03 
Soleus relative weight 
(g/kg BW) 0.41±0.01 0.38±0.02 0.49±0.01
# 0.50±0.02# 
Gastrocnemius relative 
weight 
(g/kg BW) 
4.5±0.3 4.9±0.1 4.3±0.1 4.4±0.2 
 2 Weeks 
 Control-Water 
(n=5) 
Control-
Prazosin (n=5) 
CORT-Water  
(n=9) 
CORT-Prazosin 
(n=6) 
Plasma corticosterone 
(ng/ml) 16.21± 6.5 9.6 ±0.6 296.3±34.4
# 284.7±34.2# 
Body weight  
(kg) 0.37 ± 0.005 0.37±0.01 0.25±0.008
# 0.25±0.009# 
TA relative weight 
(g/kg BW) 1.88 ± 0.04 1.88±0.03 1.57±0.04
# 1.58±0.05# 
EDL relative weight  
(g/kg BW) 0.49 ± 0.01 0.52±0.01 0.48±0.02 0.47±0.02 
Plantaris relative weight 
(g/kg BW) 0.91±0.04 0.92±0.02 0.82±0.03 0.81±0.03
# 
Soleus relative weight 
(g/kg BW) 0.45±0.009 0.40±0.02 0.54±0.02
# 0.51±0.02# 
Gastrocnemius relative 
weight 
(g/kg BW) 
5.0±0.2 5.2±0.1 4.2±0.2# 4.3±0.1# 
Values are expressed as mean ± standard error 
c, main effect of CORT-treatment, Two-way ANOVA 
#, significant difference compared to respective control group, Bonferroni post hoc 
analysis 
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Discussion: 
 The present study demonstrates that sustained exposure to elevated CORT results 
in a decrease in Ang-1 expression, which corresponds with the observed rarefaction of 
capillaries within skeletal muscle. A sustained elevation in skeletal muscle blood flow, 
induced by prazosin administration, prevents CORT-induced capillary rarefaction. 
However, both prazosin-induced angiogenesis and arteriogenesis are absent in CORT-
treated animals. CORT does not interfere with several key endothelial cell shear stress 
signaling pathways including phosphorylation of ERK1/2 and p38 and the production of 
NO, but does reduce the magnitude of increase in the phosphorylation of Ser473Akt, and 
in VEGF-A and TGFβ1 mRNA, as compared to untreated cells. These findings highlight 
the broad influence of CORT on the microvasculature and indicate that sustained 
increases in blood flow can mitigate these deleterious effects.  
The loss of capillaries in response to CORT treatment suggests the induction of 
endothelial cell apoptotic signaling or a loss of pro-survival signaling.  Previously our 
group has shown that CORT does not induce apoptosis in cultured endothelial cells 
(Shikatani et al., 2012); therefore, in the current study we assessed several factors known 
to be associated with both endothelial cell survival and angiogenesis.  Ang-1 is proposed 
to be important for the maintenance of a quiescent endothelium, structural integrity and 
endothelial cell survival through its activation of the Tie2 receptor (Brindle et al., 2006). 
The current study noted a decrease in Ang-1 after both 1W and 2W of CORT treatment, 
which paralleled CORT-mediated capillary rarefaction. In line with our observation, 
Ang-1 mRNA expression was shown to be down regulated and was postulated to 
contribute to the capillary rarefaction observed in hind-limb unloading (Wagatsuma, 
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2008), while 6 days of exposure to the synthetic GC, dexamethasone, reduced Ang-1 
mRNA expression within the mouse adrenal gland (Féraud et al., 2003).  However, Ang-
1 expression was not altered by 48 hr. CORT treatment in cultured endothelial cells, 
suggesting that CORT does not exert direct transcriptional repression of Ang-1.  In vivo, 
CORT may reduce the expression of Ang-1 mRNA from non-endothelial sources within 
the microenvironment (i.e. skeletal myocytes). Several of the cellular effects of Ang-1 are 
mediated through activation of the PI3K/Akt signaling pathway (Papapetropoulos, 2000). 
However, no change in the basal level of Akt phosphorylation (Ser473 or Thr308) was 
noted with CORT treatment. Thus, it is unlikely that a reduction in basal Akt activity 
underlies the CORT-induced capillary rarefaction, despite the established role of Akt in 
cell survival, proliferation and cell cycle progression (Cardone et al., 1998; 
Papapetropoulos, 2000; Manning and Cantley, 2007). Therefore, the mechanism through 
which reduced Ang-1 mRNA may contribute to GC-mediated capillary rarefaction 
remains to be established. 
Endothelial cell derived VEGF-A has been shown to act as an important autocrine 
pro-survival signal (Lee et al., 2007). Although previous in vitro reports have 
demonstrated that GC treatment reduces VEGF-A mRNA in cultured endothelial cells 
(Shikatani et al., 2012), the current study found that CORT-repressive effects on VEGF-
A were not sustained after 1 or 2 weeks of CORT treatment. Furthermore, the potent anti-
angiogenic factor TSP-1 was not significantly increased by CORT treatment at any of the 
time points examined. A previous study reported a transient, but not sustained, GC- 
mediated increase in TSP-1 expression (Logie et al., 2010), and such an effect would 
have been missed in the time frame of our study.  Thus, our data indicate that the 
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repression of Ang-1 expression, rather than alterations in VEGF-A or TSP-1, is the most 
plausible contributor to CORT-mediated capillary rarefaction. The apparent lack of direct 
influence of CORT on endothelial Ang-1 mRNA, when considered together with our 
prior finding that CORT treatment did not induce apoptosis in cultured microvascular 
endothelial cells (Shikatani et al., 2012), implies that CORT treatment evokes alterations 
within the skeletal muscle microenvironment that ultimately contributes to the loss of 
skeletal muscle capillaries.   
Prazosin treatment was used as a tool to examine the impact of CORT on shear 
stress dependent remodeling within the skeletal muscle microvasculature, as it has been 
shown to induce angiogenesis and arteriogenesis within skeletal muscle of healthy rats 
(Skalak and Price, 1996; Zhou et al., 1998; Milkiewicz et al., 2001). While the expected 
angiogenic and arteriogenic responses occurred within control animals in the current 
study, they were absent in CORT-treated animals. Despite the lack of angiogenic 
response, 2W prazosin treatment effectively prevented the CORT-induced loss of 
capillaries.  A partial recovery of Ang-1 mRNA level was detected at this time point.  
This effect is likely not a direct influence of blood flow on endothelial cell expression of 
Ang-1, since it was reported that shear stress does not modulate Ang-1 mRNA in cultured 
endothelial cells (Chlench et al., 2007). It is plausible that the prazosin-induced increase 
in blood flow stimulates the release of endothelial derived mediators, such as NO, which 
act as paracrine effectors of the expression of Ang-1 in neighboring cells.  Nonetheless, 
the alteration in Ang-1 mRNA is modest with prazosin treatment and by itself, may not 
explain the lack of capillary rarefaction.  It is likely that the concomitant restoration of 
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VEGF-A protein level in CORT-prazosin treated animals is an important contributor to 
the prevention of capillary rarefaction.   
The absence of an angiogenic response to prazosin in CORT-treated animals 
could be attributed to impaired shear stress activation of angiogenic signals. Shear stress 
induced angiogenesis is mediated, in part, by an increase in pro-angiogenic signaling 
involving VEGF-A (Milkiewicz et al., 2001; Uchida et al., 2015) as well as NO 
production via Akt phosphorylation of eNOS (Hudlicka et al., 2006) and a down-
regulation of anti-angiogenic factors such as TSP-1 (Bongrazio et al., 2008). In healthy 
rats, prazosin treatment has been reported to elicit an early increase in VEGF-A mRNA 
(within 2 days), preceding the increase in C:F (Milkiewicz et al., 2007). Thus, it is not 
surprising that we did not detect an increase in VEGF-A mRNA in control/prazosin 
treated animals, given the time points analyzed. Interestingly, VEGF-A mRNA increased 
after 2W of prazosin treatment within the CORT group, which may suggest that the 
angiogenic response to prazosin was delayed, but that it might have been detected if 
prazosin treatment continued beyond 2 weeks.    
Elevated blood flow is known to induce the remodeling of arterioles (Skalak and 
Price, 1996). As expected, the current study noted that in healthy control animals, 
prazosin increased the average size of SMA+ vessels, consistent with an outward 
remodeling response of arterioles to the sustained increase in blood flow. Prazosin 
induced arteriogenesis was absent in CORT-animals; this finding is corroborated by 
previous work that dexamethasone treatment impaired arteriogenesis in a mouse model of 
hind limb ischemia (Troidl et al., 2013). Arterial remodeling is regulated, in part, by 
TGFβ1 and MMP signaling (van Royen et al., 2002; Haas et al., 2007).  In the current 
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study, in vivo CORT treatment transiently reduced the mRNA levels of TGFβ1 and a 
sustained reduction in MMP2 expression. Neither prazosin treatment nor in vitro shear 
stress was able to rescue the expression of TGFβ. Furthermore, in line with our findings, 
in vitro experiments have shown that MMP2 and 9 expression are significantly reduced 
by GCs (Burnham et al., 1991; Shikatani et al., 2012). While we did not detect changes in 
TIMP1 mRNA with CORT treatment, GC were reported to increase TIMP1 mRNA in 
cultured cerebral endothelial cells (Förster et al., 2007). Taken together, the reduction in 
TGFβ1 and MMP2 portray a scenario in which CORT alters the microvascular 
environment and represses flow-induced outward arteriolar remodeling by reducing the 
production of factors that can promote smooth muscle cell proliferation and extracellular 
matrix proteolysis.  
Considering the lack of appropriate remodeling responses to prazosin treatment, 
in vitro endothelial cell culture experiments were employed to examine direct influences 
of CORT on endothelial cell shear stress responses. These data support the general 
conclusion that CORT-treated endothelial cells retain shear stress responsiveness of 
major cell signal pathways, such as pERK1/2 and p38MAPK. Interestingly, CORT did 
blunt pSer473 Akt phosphorylation in response to shear stress, both in vitro and in vivo.  
Evidence exists that phosphorylation at Thr308, and not Ser473, is required for Akt 
activation and the promotion of several downstream signaling pathways (Scheid and 
Woodgett, 2003), thus the functional consequence of reduced pSer473 Akt within the 
context of our study uncertain. Although we did not detect an alteration in shear stress 
induced NO production, a known downstream effector of Akt signaling (Dimmeler et al., 
1999), we cannot exclude a possible influence on other Akt effectors that may have an 
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impact on capillary maintenance.  It also is possible that CORT exerts influences through 
shear stress signaling pathways that were not assessed in the current study; however, 
CORT treatment did blunt the shear stress induced increases in both VEGF-A and 
TGFβ1 mRNA. Taken together these findings suggest that shear stress responsiveness is 
maintained although it is slightly blunted due to CORT pretreatment.   
A limitation of the current study is that it did not include an assessment of muscle 
blood flow.  The lack of angiogenesis and arteriolar remodeling within CORT-treated 
animals may reflect a failure to increase blood flow to the threshold level required for 
adaptive microvascular remodeling. CORT has been previously shown to elicit a 
reduction in blood flow within the temporal lobe (de Quervain et al., 2003). Thus, it is 
possible that prazosin treatment restored muscle blood flow within CORT-treated animals 
to normal baseline levels. As such, this level of shear stress was sufficient to prevent 
CORT-induced capillary rarefaction but not to induce further capillary growth.  
The capillary network plays an important role in establishing the efficacy of 
insulin delivery to skeletal myocytes, thus having the potential to regulate insulin 
sensitivity and whole body metabolic homeostasis (Lillioja et al., 1987; Kusters and 
Barrett, 2015).  Recently, the prazosin-induced increase in skeletal muscle capillary 
content was shown to improve insulin sensitivity and subsequent glucose disposal in 
healthy rats (Akerstrom et al., 2014). Our group has also found that C:F correlates 
positively with insulin sensitivity in CORT-treated animals (Dunford et al. 2016), 
indicating that the prevention of capillary rarefaction by prazosin can exert beneficial 
metabolic influences. These findings highlight the importance of assessing the molecular 
regulation of capillary rarefaction and potential ways of preventing it.     
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 The current study demonstrates that CORT treatment evokes alterations within the 
skeletal muscle microenvironment that contributes to the loss of skeletal muscle 
capillaries.  This may be due in part to sustained reduction in Ang-1 expression. Prazosin-
induced augmentation in microvascular shear stress prevents CORT-induced capillary 
rarefaction, but is unable to elicit angiogenesis or arteriogenesis. Taken together these 
findings suggest that endothelial shear stress signaling is maintained, albeit slightly 
blunted, with prolonged CORT-treatment, thereby providing a tool for elevated muscle 
blood flow to prevent the deleterious effects of elevated levels of GCs.  
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Chapter Summary: 
Sustained elevations in circulating glucocorticoids (GCs) induce hypertension and reduce 
skeletal muscle microvascular content, but little is known of the underlying mechanisms. 
We hypothesized that GC-mediated hypertension and capillary rarefaction would be 
prevented by treatment with Tempol, a reactive oxygen species (ROS) scavenger, as well 
as by prazosin, an α1 adrenergic receptor antagonist.  Rats were implanted with 
corticosterone (CORT) or control pellets and subsequently treated for 2 weeks with 
Tempol (1 mmol/L) or prazosin (50mg/L). 2 weeks of CORT significantly elevated 
systolic blood pressure and reduced skeletal muscle blood flow. Reduced eNOS and 
increased endothelin-1 mRNA levels were detected after 1 week CORT, suggestive of 
GC-induced alterations in vascular tone.  Protein carbonylation, an indicator of oxidative 
stress, was substantially increased in muscle after 1 week CORT. This was accompanied 
by a corresponding reduction in glutathione, ROS buffering, levels.  While CORT 
reduced NADPH oxidase subunit expression within whole muscle, 600 nM CORT (48 
hours) increased mRNA of NOX1 in cultured rat skeletal muscle endothelial cells. 
Tempol alleviated oxidative stress and was partially effective in attenuating hypertension, 
but exerted no rescue of skeletal muscle microvascular rarefaction. Conversely, prazosin 
ameliorated all of these deleterious effects of CORT and the reduction in systolic blood 
pressure was maintained upon drug cessation. Taken together, the current study 
demonstrates that CORT reduces muscle blood flow and increases systolic pressure, 
which involves both increases in oxidative stress and a shift to a vasoconstrictor profile.  
The capacity of prazosin but not Tempol to prevent CORT-induced microvascular 
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rarefaction highlights the importance of muscle blood flow in the maintenance of 
microvascular content, which in turn, will impact overall cardiovascular health.  
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Introduction: 
Glucocorticoids (GCs) are steroid hormones that exert a strong angiostatic 
influence (Folkman, 1971; Small et al., 2005), induce skeletal muscle capillary 
rarefaction (Shikatani et al., 2012; Mandel et al., 2016) and hypertension (Vogt and 
Schmid-Schobein, 2001; Bachhav et al., 2011; van Raalte et al., 2013; Baum and Moe, 
2008). While the precise mechanisms mediating the development of GC-induced 
hypertension are unclear, vascular alterations that are generally known to contribute to 
hypertension include excessive vasoconstriction (Yang and Zhang, 2004) and/or 
microvascular rarefaction (Humar et al., 2009). These alterations may occur due to 
changes in nitric oxide (NO) bioavailability (Watson et al., 2008), vessel perfusion 
(Humar et al., 2009) or reactive oxygen species (ROS) levels (Zhang et al., 2004; 
Staiculescu et al., 2014). Alteration to one or more of these factors due to GC excess 
could be an important contributor to GC-mediated hypertension.  
Within the vasculature, moderate levels of ROS can regulate several cellular 
processes including cell growth, proliferation and apoptosis (Zhang and Gutterman, 
2007). Cellular sources of ROS include mitochondrial respiration (Han et al., 2001), 
NADPH oxidase (Nauseef, 2008), xanthine oxidase (Garattini et al., 2003) and eNOS 
uncoupling (Marchesi et al., 2009).  The excessive production of ROS and subsequent 
oxidative stress has been shown to play a pivotal role in the development of hypertension 
(Montezano and Touyz, 2014).  ROS can impact the vasodilator /vasoconstrictor balance 
through reduced NO and increased endothelin-1 (ET-1) expression thereby increasing 
vascular tone (Kim et al., 2006; Montezano and Touyz, 2014). Elevated ROS also may 
induce endothelial cell apoptosis and skeletal muscle microvascular rarefaction 
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(Kobayashi et al., 2005). Tempol is a stable cell permeant piperidine nitroxide that acts as 
a superoxide dismutase mimetic (Wilcox and Pearlman, 2008). Tempol has been shown 
to reduce blood pressure in the spontaneously hypertensive rat model (Schnackenberg et 
al., 1998) and to protect lipids and proteins from oxidative damage (Damiani et al., 
2000). Furthermore, dexamethasone-induced hypertensive rats experience a reduction in 
blood pressure with concurrent Tempol treatment (Zhang et al., 2004).  
It has been recently established that skeletal muscle microvascular rarefaction is 
elicited by GC excess (Shikatani et al., 2012; Mandel et al., 2016). Alterations in skeletal 
muscle microvascular content are an important determinant of overall peripheral 
resistance (Greene et al., 1989), thus providing a mechanism through which 
microvascular rarefaction contributes to the development/exacerbation of hypertension 
(Greene et al., 1989; Humar et al., 2009). Furthermore, hypertension is a potent stimulus 
for microvascular rarefaction (Hansen-Smith et al., 1996) thereby creating a vicious and 
deleterious loop. While our group has established a role for GC excess in eliciting 
microvascular rarefaction, the instigating mechanisms are still unclear.  
Therefore, the current study set out to examine the role of GC-induced increases 
in oxidative stress, which may contribute to the altered microvascular content, vascular 
tone and blood pressure regulation associated with GC excess. We hypothesized that both 
GC-mediated hypertension and capillary rarefaction are a consequence of increased 
oxidative stress and would be prevented with concurrent administration of Tempol. We 
compared the influence of Tempol to that of the anti-hypertensive drug prazosin, which is 
a selective α1-adrenergic receptor antagonist that induces skeletal muscle angiogenesis in 
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healthy animals (Ziada et al. 1989; Zhou et al. 1998; Rivilis et al. 2002; Gee et al. 2010) 
and prevents GC-induced capillary rarefaction (Mandel et al., 2016).   
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Materials and Methods: 
All animal experiments were approved by York University Animal Care Committee and 
conducted in accordance with the Canadian Council for Animal Care Guidelines.  
Animal Protocol 
Male Sprague Dawley rats (initial weight 200 to 250g) were purchased from Charles 
River Laboratories (Montreal, QC, Canada). Rats were housed in the York University 
Vivarium in 12 hour light-dark cycle. After 7 days acclimation, animals were 
anesthetized by isoflurane inhalation and were implanted with four 100mg wax (control) 
or CORT pellets (C2505, Sigma-Aldrich, Oakville, Ontario, Canada) via subcutaneous 
incision in the mid-scapular region, as described previously (Shpilberg et al., 2012). Rats 
recovered in individual cages and were given ampicillin (20mg/kg body weight) in their 
drinking water for 2 days after which they were given regular water.  All animals were 
fed a standard rodent chow diet (14% fat, 54% carbohydrate, 32% fat; 3.0 calories/g) ad 
libitum.  
Protocol 1: The tibialis anterior (TA) and gastrocnemius muscles (N=10) from a 
previously conducted experiment (Mandel et al., 2016) were used for mRNA and 
glutathione assessments. This subset of animals, termed 1W CORT, was either control-
water or CORT-water treated for 9 days prior to tissue collection.  
Protocol 2: Control and CORT groups (N=8) given regular drinking water were used in 
this protocol to assess the degree of hypertension elicited by CORT treatment. The 
animals had BP taken on D0, prior to pellet implantation and on D4, 7, 14 and 16 post 
pellet implantation.  
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Protocol 3: Control and CORT groups (N=36) were given regular drinking water (CORT-
water and con-water), drinking water containing prazosin (50 mg/L; P7791, Sigma 
Aldrich Canada) (CORT-prazosin and con-prazosin), or drinking water containing 
Tempol (1 mmol/L, 176141, Sigma Aldrich Canada) (CORT-Tempol, and con-Tempol). 
This dose of prazosin has previously been shown to prevent GC-mediated capillary 
rarefaction (Mandel et al., 2016) and this dose of Tempol has been previously shown to 
significantly reduce blood pressure in male Sprague Dawley rats treated with 
dexamethasone (Zhang et al., 2004). Prazosin or Tempol treatment began on day 2, and 
continued for 2 weeks. On day 15, drinking water containing prazosin or Tempol was 
replaced with untreated drinking water. Based on the pharmokinetics of both prazosin 
and Tempol, it was presumed that these drugs would no longer exert functional effects at 
the time of D16 measurements (Jaillon, 1980; Ueda et al., 2003). 
Blood Pressure Assessment 
Systolic blood pressure was assessed non-invasively via tail plethysmography (LE 5001 
Pressure Meter, Harvard Apparatus) on days 0, 4, 7, 14 and 16 days while animals were 
lightly sedated (isoflurane inhalation) and body temperature was maintained. D16 blood 
pressure was assessed 18 hours after removal of prazosin or Tempol from the drinking 
water. 
Hind-limb muscle blood flow 
Skeletal muscle blood flow was assessed on D16, using a microsphere protocol modified 
from (Deveci and Egginton, 1999).  Briefly, animals were anesthetized with isoflurane 
and fluorescent microspheres (500,000 spheres, 15µm in diameter, in 0.5 ml PBS) 
(Molecular Probes, FluoSpheres, #F8844) were injected directly into the left ventricle.  
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The brain, extensor digitorum longus (EDL) and soleus were immediately collected and 
flash frozen in liquid nitrogen. For analysis, tissue was incubated in 2M 0.5% tween 
ethanoic KOH for 24 hours at 37°C. After digestion, tubes were spun at 3000RPM for 15 
minutes, followed by two ethanoic-tween washes. The microsphere pellet was re-
suspended in xylene and the fluorescent signal was detected with a microplate reader 
(CytationTM 3, Biotek, Vermont USA). The normalized fluorescent intensity (FI) was 
calculated relative to tissue mass (FI/100g tissue).  Relative blood flows were estimated 
by expressing the normalized FI of EDL and soleus muscles as a ratio to normalized 
brain FI, to discount the impact of artifacts associated with animal-to-animal variability 
in the microsphere injection.  Muscle flow was normalized to the brain flow, with the 
assumption that brain blood flow would not be affected by GC treatment, as 
autoregulatory mechanisms maintain constant brain blood flow under a wide range of 
physiological and pathological conditions (Paulson et al., 1989; Strandgaard and Paulson, 
1995).  
Tissue Isolation 
Hind-limb skeletal muscles were removed under isoflurane anesthesia.  Muscles were 
weighed and snap frozen in liquid nitrogen for RNA and protein analyses or frozen in 
liquid nitrogen cooled isopentane for histology.  
Bioinformatics search for glucocorticoid response elements within NADPH oxidase 
subunits 
A bioinformatics search was conducted using the MultiTF function within ECR browser 
(Ovcharenko et al., 2004) to identify the multi-species (murine and human) conserved 
consensus glucocorticoid response elements (GRE), specifically examining the genes that 
 108!
encode NADPH-oxidase subunits: NOX1, NOX2 (gp91phox), NOX3, p22phox, p47phox, 
p40phox and p67phox. The search focused on identification of putative GRE (with a 
predefined matrix similarity of 0.85 or greater) within the “start” region of these genes, 
which was defined as +/-3 kb relative to the first exon.  
RNA extraction and Real Time qPCR 
RNA was isolated from TA muscle using the Qiagen RNeasy Fibrous Tissue Mini Kit 
(74704, Qiagen, Toronto, ON Canada) as per the manufacturer’s instructions. RNA was 
isolated from cultured endothelial cells using cells to cDNA lysis buffer (#AM8723, 
Invitrogen Canada; Burlington, ON Canada). RNA was reverse transcribed using MMLV 
reverse transcriptase (New England Biolabs, Whitby ON Canada). cDNA were analyzed 
by Taqman qPCR using qPCR mastermix (Invitrogen Canada) and Taqman probes for rat 
HPRT (Rn01527840), eNOS (Rn02132634), α-1 adrenergic receptor (Rn00567876), 
NOX1 (Rn00586652_m1), NOX2 (gp91phox, Rn00576710_m1), NOX3 
(Rn01430441_m1), p47phox (Rn00586945_m1) & ET-1 (Rn00561129_m1) using the ABI 
7500 Fast PCR system (Invitrogen Canada). For each sample, the comparative Ct method 
was used to determine mRNA expression of target genes relative to the housekeeping 
gene HPRT and expressed as 2-ΔCt. 
Muscle Histology and cell staining 
10µm cryosections of TA muscle were fixed with 3.7% paraformaldehyde and stained 
with fluorescein isothiocyanate-conjugated Griffonia simplicifolia isolectin B4 (1:100; 
Vector Laboratories, Burlington ON, Canada) and anti-smooth muscle actin-Cy3 (1:300; 
C6198, Sigma Aldrich, Oakville ON, Canada). Sections were viewed using a Zeiss M200 
inverted microscope with 20x objective.  Images were captured using a cooled CCD 
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camera using Metamorph imaging software. Capillary-to-fiber (C:F) counts were 
averaged from 3 to 4 independent fields of view per rat by a blinded observer.  
Skeletal muscle glutathione levels  
Frozen muscle samples were homogenized in a 50mM Tris based buffer containing 
20mM boric acid, 2mM L-serine, 20µM acivicin and 5mM N-ethylmaleimide. Muscle 
homogenate was acidified using trichloroacetic acid for reduced glutathione (GSH) 
determination, and 15% perchloric acid (PCA, Caledon Laboratories Ltd, Georgetown, 
Canada) for oxidized glutathione (GSSG). NEM irreversibly binds to GSH producing a 
GS-NEM conjugate, preventing auto-oxidation of glutathione during sample preparation. 
Samples were centrifuged at 20,000 RCF for 5 min (4oC). The TCA-acidified muscle 
sample was then used for GSH analyses by HPLC (Agilent 1100) with column separation 
performed using a Zorbax high performance analytical 4.6x150mm 5µm column 
(Agilent, Santa Clara, USA). PCA-acidified muscle sample was diluted (1:5) in 0.5M 
NaOH. Samples were then incubated in the dark with 0.1% O-pthalymide (OPA, Sigma-
Aldrich, Oakville, Canada) creating a GS-OPA conjugate and were then ready for GSSG 
quantification by HPLC as described above. Prior to acid deproteination, a sample of 
muscle homogenate was removed for protein concentration analysis using a Pierce BCA 
protein assay kit (Thermo, Fisher Scientific, Waltham, USA). All values were referenced 
to protein concentration and reported in µmol/g protein. 
GSH was determined as previously described (Giustarini et al., 2013). Briefly, 0.25% 
glacial acetic acid with 6% acetonitrile was used for mobile phase at a flow rate of 
1.25ml/min. GS-NEM conjugate was detected using a using a modular variable 
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wavelength detector at 265nm wavelength. Values were referenced to a standard curve of 
reduced glutathione (Sigma-Aldrich, Oakville, Canada) and expressed as µmol/g protein. 
Reduced glutathione was determined by separation by HPLC as previously described 
(Kand’ár et al., 2007). Briefly, 25mM Na2HPO4 in HPLC grade water with 15% methanol 
at 0.5ml/min was used for mobile phase separation at a flow rate 0.5ml/min. Following 
column separation, samples flowed through a flow-through cuvette (FireflySci 8830, 
New York, USA) in a PTI QuantaMaster 40 spectrofluorometer (Horiba, New Jersey, 
USA). GS-OPA conjugate was excited at 350nm and emission was detected at 420nm. 
Values were referenced to a standard curve of GSSG (Sigma-Aldrich, Oakville, Canada) 
and expressed as µmol/g protein. 
Total glutathione was calculated as the sum of GSH and GSSG values.  
Oxidative stress 
Protein carbonylation was assessed as an indirect measure of accumulated oxidative 
stress (Davies et al., 1999) using a Protein Carbonyl Colorimetric Assay Kit (Caymen 
Chemical Company, # 10005020, Ann Arbor MI). Briefly, 100mg of tissue was extracted 
from the TA or gastrocnemius muscle in 1X PBS containing 1mM EDTA. Protein 
carbonyl content was assessed as per the manufacturer’s instructions and was expressed 
as nmol/µg of total protein.  
Cell culture experiments 
Skeletal muscle microvascular endothelial cells were isolated from the TA muscle of 
male Sprague Dawley rats as described previously (Han et al., 2003).  Cells were cultured 
with Dulbecco’s Modified Eagle Medium (Invitrogen) supplemented with 10% heat 
denatured FBS, 1mM sodium pyruvate, 1mM Glutamax (Invitrogen), 50 units penicillin, 
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0.5mg/ml streptomycin and 1.25µg/ml Fungizone (Gibco). Cells were used for 
experiments between passages 4 to 6. Endothelial cells were plated on 12 well plates and 
subsequently treated with 600 nM CORT for 48 hours (Control or CORT), a dose that 
previously was shown to inhibit angiogenic behavior (Small et al., 2005; Shikatani et al., 
2012). RNA was isolated from cultured endothelial cells using cells-to-cDNA lysis buffer 
(#AM8723, Invitrogen Canada; Burlington, ON Canada). 
Statistical Analysis 
All results were expressed as mean ± SEM and analyzed by one-way or two-way 
ANOVA with subsequent Bonferroni post hoc tests (Prism4; Graphpad software Inc; La 
Jolla, CA, USA). Systolic blood pressure was analyzed using a proc mixed of general 
linear model for a repeated measures analysis using SAS software, to account for 
repeated measures, the various conditions and treatment groups.  P < 0.05 was considered 
statistically significant.   
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Results: 
For full animal characteristics and details seen supplementary Table 4.1 
CORT influence on blood pressure and skeletal muscle blood flow  
Systolic blood pressure was significantly elevated after 4 days of CORT-treatment 
and remained elevated throughout the duration (D7 & 14) of the experiment (Figure 
4.1A). After 2W of CORT treatment, systolic blood pressure was 78% higher than 
control animals (157±8 vs. 87±5 mmHg) (Figure 4.1A). CORT significantly decreased 
relative EDL blood flow (Figure 4.1B) but did not significantly alter relative soleus blood 
flow (35.1±16.5 vs. 19.2±11.2, P>0.05).  eNOS mRNA was significantly reduced while 
ET-1 mRNA concurrently increased in TA muscle with 1W of CORT treatment (Figure 
4.1C & D), suggesting an increase in vasoconstrictor signals.  α1 adrenergic receptor 
mRNA expression was not significantly altered by 1W of CORT treatment (Figure 4.1E).  
CORT induced oxidative stress  
Augmented ROS levels are postulate to result in increased vascular tone 
(Staiculescu et al., 2014). ROS can accumulate due to increased ROS production and/or 
reduced ROS buffering. The glutathione system plays a critical role in protecting cells 
from ROS-mediated damage (Dringen, 2000).  Both total glutathione and GSH (reduced 
glutathione) were significantly reduced with 1W of CORT treatment (Figure 4.2A & B), 
indicating a greatly diminished capacity for ROS buffering.  Protein carbonylation was 
significantly increased in the CORT-treated muscles (Figure 4.2C).  
NADPH oxidase is a major producer of cellular ROS (Siuda et al., 2014), thus an 
alteration in the expression of NADPH oxidase subunits may underlie the observed 
increased oxidative stress. A bioinformatics search revealed that several NADPH oxidase 
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subunits contained one or more conserved GC receptor-binding elements within their 
start region; NOX1 has 2 conserved sites, NOX2 has 4 conserved sites and NOX3 has 3 
conserved sites within the start region (Figure 4.3A).  p47phox was found to have 2 
conserved sites, however these were located greater than 5 kb distal to the first exon. The 
subunits p22phox, p67phox and p40phox did not have any conserved GRE sequences and thus 
were excluded from further analysis.  
NOX1, NOX2 and p47phox mRNA were significantly reduced within whole 
muscle homogenates after 1W CORT (Figure 4.3B-D). NOX3 levels were below the 
level of detection. Conversely, NOX1 mRNA was significantly increased in cultured 
microvascular endothelial cells after 48 hours of CORT (Figure 4.3E). No significant 
changes in p47phox were seen (Figure 4.3F), and both NOX2 and NOX3 mRNA were 
undetectable in the cultured rat endothelial cells. These data indicate that CORT may 
repress whole muscle expression of NADPH oxidase subunits while increasing the level 
of NOX1 in endothelial cells. 
Influence of Tempol or prazosin treatment on CORT-induced hypertension and 
capillary rarefaction 
To investigate the role of oxidative stress on the development of CORT-induced 
hypertension and capillary rarefaction, we co-treated rats with the superoxide scavenger 
Tempol. We compared the influence of Tempol with that of the α1-adrenergic receptor 
antagonist prazosin, which has established influences both as an anti-hypertensive 
(Jaillon, 1980) as well as a preventer of GC-induced capillary rarefaction (Mandel et al., 
2016).  As anticipated, Tempol was effective in reducing CORT-induced oxidative stress, 
as evidenced by the significant reduction in protein carbonylation with 2W Tempol co-
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treatment when compared to CORT alone (Figure 4.4A). Prazosin co-treatment also 
abolished the CORT-induced increase in protein carbonylation (Figure 4.4A). 
GC treatment elicited substantive increases in systolic blood pressure after as little 
as 4 days (Figure 4.4B). Tempol and prazosin each significantly abrogated CORT-
induced hypertension.  The prazosin-induced reduction in systolic blood pressure was 
detectable at the 4 day time-point, whereas Tempol did not exert a significant reduction 
in systolic blood pressure until the 7 day time-point (Figure 4.4B). Neither Tempol nor 
prazosin significantly affected systolic blood pressure in control rats (Figure 4.4B & C). 
After 14 days, systolic blood pressure was 51% higher in CORT-water vs. control-water 
treated rats (Figure 4.4C).  The percent increase in systolic blood pressure in both the 
CORT-prazosin and CORT-Tempol groups was significantly less than observed with 
CORT-water.  However, only the CORT-prazosin group displayed a systolic blood 
pressure that was not significantly different from its respective control condition (Figure 
4.4C).  Alterations in heart rate over the course of the experiment see supplementary 
Figure 4.1.  
The depressor influences of prazosin and Tempol may be a consequence of 
functional improvements, such as a reduction in ROS and a shift in the balance between 
vasodilators vs. vasoconstrictors, or may be associated with improved structural 
alterations in the vasculature, such as outward remodeling of small muscular arteries and 
arterioles.  While functional alterations may depend on the continued presence of the 
drugs, structural remodeling should continue to exert a positive influence on systolic 
blood pressure without the drug being present.  Thus, we reasoned that functional and 
structural influences could be distinguished from one another by reassessing blood 
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pressure after the removal and clearance of prazosin or Tempol. As expected, systolic 
blood pressure at day 16 remained consistently elevated in the CORT-water group, and 
systolic blood pressure remained unaltered compared to day 14 in all control groups 
(Figure 4.4D). Notably, systolic blood pressure in CORT-prazosin animals was not 
different at day 16 relative to day 14 values, and remained significantly lower than in the 
CORT-water group (Figure 4.4D). However, the removal of Tempol resulted in a 
significant increase in systolic blood pressure compared to the respective control group, 
such that systolic blood pressure in this group was no longer different from that of 
CORT-water animals (Figure 4.4D).  
2W CORT caused a significant reduction in EDL C:F (Figure 5A &B), in line 
with previous reports (Mandel et al., 2016). CORT-mediated capillary rarefaction was 
prevented by concurrent prazosin but not Tempol treatment (Figure 4.5B &C). 
Furthermore, Tempol did not exert an angiogenic effect within control animals (Figure 
4.5B & C). The lack of angiogenic influence of Tempol was confirmed by analysis of 
C:F in the TA muscle (control: 1.71±0.03; control-Tempol:1.73±0.03; CORT: 1.51±0.05; 
CORT-Tempol: 1.46±0.06).  
 A significant negative correlation between day 7 systolic blood pressure and day 
16 skeletal muscle C:F was detected when comparing control with CORT (r= -0.84; 
Figure 4.5C) and CORT-water with CORT-prazosin (r=-0.77; Figure 4.5D). This may 
suggest that systolic blood pressure is a key determinant of C:F.  However, this 
relationship was not maintained in the CORT-Tempol group (r=-0.16; Figure 4.5E). 
These findings highlight that alterations in systolic blood pressure are not solely 
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responsible for alterations in microvascular content and that additional factors may be 
important regulators of C:F in CORT-treated animals. 
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Supplementary Table 4.1: Body composition of control or two week CORT-treated 
animals with or without concurrent Tempol or prazosin treatment  
 
!
!
control!
water!!
(n=6)!
control!
prazosin!
(n=6)!
control!
Tempol!
(n=6)!
CORT!water!
(n=6)!
CORT!
prazosin!
(n=6)!
CORT!
Tempol!
(n=6)!Body!Weight!(g)! 0.348±0.008! 0.369±0.0046! 0.358±0.01! 0.22±0.004#! 0.024±!0.007#! 0.23±!0.009#!Absolute!TA!weight!(g)! 0.56±0.03! 0.62!±0.02! 0.59!±0.03! 0.32!±0.009#! 0.39!±0.03#! 0.36±!0.02#!Relative!TA!weight!(g/kg!BW)! 1.6!±0.06! 1.7±!0.06! 1.7!±0.05! 1.5±0.05! 1.6!±0.1! 1.6±!0.05!Absolute!EDL!weight!(g)! 0.16!±0.004! 0.17!±0.004! 0.17±!0.006! 0.10!±0.003#! 0.10!±0.01#! 0.11!±0.004#!Relative!EDL!weight!(g/kg!BW)! 0.45!±0.01! 0.46±!0.01! 0.47±0.007! 0.48!±!0.01! 0.42!±!0.05! 0.49!±!0.01!Abs!Soleus!weight!(g)! 0.13!±0!01! 0.14±0.005! 0.15!±0.008! 0.11!±0.006#! 0.092!±0.01#! 0.11±0.003#!Relative!Soleus!weight!(g/kg!BW)! 0.39±!0.02! 0.39!±0.01! 0.41±!0.02! 0.5±!0.03#! 0.38!±0.05! 0.49±!0.02!!#!Significant!difference!compared!to!respective!control!group!
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Discussion:  
The current study demonstrated that both superoxide scavenging and α1 
adrenergic receptor inhibition reduced GC-mediated oxidative stress and elevated systolic 
blood pressure.  The elevation in systolic blood pressure preceded GC-induced capillary 
rarefaction suggestive of a role for elevated systolic blood pressure in skeletal muscle 
microvascular rarefaction.  However, α1 adrenergic receptor inhibition, but not ROS-
scavenging, prevented GC-mediated capillary rarefaction and maintained a reduction in 
systolic blood pressure upon drug cessation. These findings indicate that ROS contribute 
significantly to GC-mediated hypertension but that alleviation of oxidative stress is not 
sufficient to prevent capillary rarefaction.  The prevention of capillary rarefaction by α1 
adrenergic receptor inhibition points to the critical role for local skeletal muscle blood 
flow in the maintenance of microvascular content.  
Relative basal blood flow to the glycolytic EDL muscle was significantly reduced 
after 2W CORT. Our data suggest a CORT-induced shift in vascular tone in favor of 
sustained vasoconstriction due to a decrease in eNOS with a concurrent increase in ET-1 
mRNA. Previous studies have postulated that GCs modulate vascular tone through 
alterations in circulating hormones and/or potentiating the vasoconstrictor effects of 
catecholamines or angiotensin II (Ullian, 1999; Iuchi et al., 2003). We did not observe 
changes in α1 adrenergic receptor mRNA expression in CORT-treated animals.  Rather, 
our results are consistent with the report that GC treatment reduced reactive hyperemia in 
humans, which was postulated to be a consequence of reduced NO production and/or 
bioavailability (Iuchi et al., 2003).   
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The current study found that oxidative stress was elevated after 1W and 2W of 
CORT treatment, as evidenced by increased protein carbonylation. CORT treatment 
significantly reduced total glutathione levels and increased endothelial cell NOX1 
mRNA. These findings imply that CORT increases oxidative stress through both a 
reduction in ROS buffering capacity and increased vascular ROS production. 
Surprisingly, we found that 1W CORT treatment reduced the transcript levels of NADPH 
oxidase subunits, NOX1, NOX2 and p47phox, in whole muscle lysates, which suggests 
that the GC influences on NOX expression may be cell type specific. Previous 
investigations are in support of the abovementioned findings. For example, increased 
nitrotyrosine levels were reported in the vasculature of patients with elevated GC (Iuchi 
et al., 2003). As well, rats treated with dexamethasone for 2 weeks had significant 
reductions in total glutathione levels within blood and skeletal muscle (Orzechowski et 
al., 2000). Lastly, GC treatment increased NOX2 protein levels in cultured endothelial 
cells (Muzaffar et al., 2005), but was reported to reduce NOX activity within cultured 
smooth muscle cells (Marumo et al 1998). An advantage of the current study is that we 
assessed both markers of vascular function as well as oxidative stress within the same 
animal model and that these observations were extended to consider their involvement in 
capillary rarefaction and augmented systolic blood pressure.    
GC-mediated augmentation of ROS may play a direct role in the regulation of 
vascular tone. Dexamethasone induces the production of hydrogen peroxide, coinciding 
with reduced levels of NO, in cultured endothelial cells (Iuchi et al., 2003) This will 
impact NO-dependent vasodilation, and also will relieve the repressive influence of NO 
on NOX expression (Muzaffar et al., 2004). Therefore, the reduction in eNOS mRNA 
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detected in GC-treated animals combined with ROS-mediated reduction in NO 
bioavailability, may contribute to augment NOX subunit expression. Additionally, ROS 
can increase the generation or release of the vasoconstrictor ET-1 (Ruef et al., 2001). 
Thus, at the vascular level, the increased oxidative stress detected in the current study 
likely contributes to the alterations in the vasoconstrictor-vasodilator balance, thus 
influencing systolic arterial pressure.  
Computational modeling experiments have suggested that microvascular 
rarefaction contributes to increased blood pressure (Greene et al., 1989), which is 
supported by studies in both hypertensive humans and in animal models (Hansen-Smith 
et al., 1996; Noon et al., 1997; Humar et al., 2009). In the current study, we reported an 
increase in systolic blood pressure after 4 days of CORT treatment, substantially prior to 
the occurrence of capillary rarefaction that is detected after 2W but not 1W of CORT-
treatment (Mandel et al., 2016). The current study demonstrates a significant inverse 
correlation between augmented systolic blood pressure after 1W CORT and C:F after 2W 
CORT. Our study is more consistent with the postulation that augmented systolic blood 
pressure itself is a driving force behind capillary rarefaction (Hansen-Smith et al., 1996). 
Nonetheless, capillary rarefaction may in turn contribute to or further aggravate GC-
induced hypertension.   
Both Tempol and prazosin effectively reduced systolic blood pressure in GC-
treated rats, in line with previous research (Jaillon, 1980; Schnackenberg and Wilcox, 
1999; Sainz et al., 2005; Wilcox and Pearlman, 2008). This anti-hypertensive effect was 
moderately delayed in Tempol-treated rodents as compared to those administered 
prazosin. Additionally, the anti-hypertensive influence of Tempol was rapidly lost after 
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removal of the drug. These findings suggest that the superoxide scavenging effect of 
Tempol did not elicit sustained structural or functional adaptations within the skeletal 
muscle microvasculature.  
 In contrast to prazosin, 2W of Tempol treatment did not induce skeletal muscle 
angiogenesis in healthy rats, which may indicate that there is minimal superoxide 
generation under resting conditions in the vasculature of healthy animals.  Surprisingly, 
Tempol failed to prevent capillary rarefaction in the GC-treated animals despite its 
depressor influence on systolic blood pressure, suggesting that superoxide scavenging by 
itself is an insufficient angiogenic stimulus.  The dissimilar effects of Tempol and 
prazosin on capillary content may be due to the greater reduction in blood pressure 
achieved with prazosin, but it likely also reflects differences in the location/mode of 
action of prazosin compared to Tempol.  Due to the high level of tonic sympathetic nerve 
activation (Korthuis, 2011) and the high density of alpha-adrenergic receptors (Stanfield, 
2011) within the skeletal muscle under resting conditions, prazosin elicits vasodilation 
predominantly within the skeletal muscle that is associated with an approximately 
threefold increase in skeletal muscle blood flow (Williams et al., 2006). Conversely, the 
ROS-scavenging effects of Tempol occur throughout the entire vasculature, resulting in 
reduced resistance within many vascular beds. Therefore, the degree of influence on 
skeletal muscle blood flow is predicted to be more modest with Tempol compared to that 
of prazosin.  In support of this idea, Tempol treatment was shown to reduce systemic 
blood pressure without improving skeletal muscle blood flow in rats with metabolic 
syndrome (Frisbee et al., 2011).  A limitation of our experimental design is that we were 
not able to compare the extent of prazosin and Tempol-mediated alterations in skeletal 
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muscle blood flow because the end point of our experiment was 18 hours after removal of 
drugs. Nonetheless, the findings from our study point to the importance of improved 
skeletal muscle blood flow, rather than oxidative stress itself, in the preservation of 
capillary content.   The maintenance of capillary content constitutes a structural 
adaptation that may have contributed to the maintenance of a reduced systolic blood 
pressure upon prazosin cessation.  
GC-treatment also elicits skeletal muscle atrophy, with greatest reduction in fiber 
cross-sectional area occurring in type IIbx fibers in rodents (Beaudry et al., 2015; 
Dunford et al., 2016). Interestingly, relative soleus muscle weight is unaffected by CORT 
treatment, suggesting that oxidative muscles do not undergo extensive GC-mediated 
atrophy (Schakman et al., 2008; Shpilberg et al., 2012). Likewise, we found that 2W 
CORT-treatment reduced blood flow within the EDL but not the soleus muscle. These 
findings suggest a possible association between skeletal muscle atrophy and reduction in 
blood flow, which warrants further investigation.  
In summary, the current study demonstrated that sustained elevations in GCs 
augmented oxidative stress, likely due to both increased ROS production and decreased 
ROS buffering. Oxidative stress may contribute to GC-mediated alterations in vascular 
tone and muscle blood flow. Although partially effective in attenuating the GC-mediated 
elevation in systolic blood pressure, Tempol alleviated oxidative stress but did not 
prevent skeletal muscle capillary rarefaction.  Prazosin also attenuated oxidative stress 
and lowered systolic blood pressure. However, unlike Tempol, prazosin prevented 
capillary rarefaction and maintained a reduction in systolic blood pressure upon drug 
cessation. These findings suggest an important role for adrenergic control of muscle flow 
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and oxidative stress in the maintenance of microvascular content, which will in turn have 
an impact on overall cardiovascular health.   
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Chapter 5: Concluding remarks 
 In healthy adults, the skeletal muscle microvasculature responds, adapts and 
remodels to a multitude of stimuli. Microvascular remodeling results from the activation 
of signaling pathways and appropriate responses to said signals within the 
microenvironment. This involves communication between the different cell types within 
the microenvironment including skeletal myocytes, endothelial cells and smooth muscle 
cells. Additionally, vascular remodeling requires the coordinated balance between 
proteases and their inhibitors as well as the balance between pro-angiogenic and anti-
angiogenic factors (Pepper, 2001). Thus, skeletal muscle microvascular remodeling is a 
highly regulated and complex process. However, as a result of a variety of diseases and 
other pathological conditions, the remodeling response can become impaired.   
 The current study set out to investigate signaling within the microenvironment in 
response to several different stimuli. Firstly, I used Timp1-/- mice with the intention of 
perturbing the proteolytic balance. The goal was to examine skeletal muscle 
microvascular remodeling due to alterations in flow in Timp1-/- compared to WT mice. 
Secondly, the deleterious effects of GCs on skeletal muscle capillarization have been 
documented (Shikatani et al., 2012); therefore, I examined factors that may be 
contributing to this phenotype and possible signaling pathways that can be altered to 
prevent its occurrence. Lastly, I further examined the GC model to determine how 
alterations to the skeletal muscle microvasculature may be impacting systolic blood 
pressure and which pathway(s) may be responsible. Employing these different animal 
models provided a comprehensive examination of different component/aspects of the 
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microvascular microenvironment, which mediates microvascular health and remodeling 
capabilities. 
5.1: Summary of findings 
The mouse model of TIMP1 deficiency was used to test the hypothesis that 
appropriate alterations in the proteolytic balance are integral for microvascular 
remodeling. While the loss of TIMP1 did not result in overt health complications, it 
impaired microvascular development. These findings are suggestive of impairments 
within the microenvironment of Timp1-/- mice, which negatively impacts normal blood 
vessel growth and/or maturation (Figure 5.1A).  Contrary to our hypothesis, the deletion 
of TIMP1 did not appear to significantly increase proteolytic activity within the 
microenvironment thereby resulting in vascular remodeling (Figure 5.1A). Although the 
correct responses to altered flow (augmented VEGF-A and/or eNOS mRNA) occurred 
within the microenvironment of Timp1-/- mice, this was insufficient to elicit angiogenesis 
or arteriogenesis. These findings could imply an issue with signal transmission; i.e. the 
cells within the microenvironment can initiate but not respond to normal responses, 
thereby culminating in a lack of vascular remodeling. One likely possibility, which was 
not assessed in the current experiment, is alterations in the expression of specific VEGF 
isoforms, as different VEGF isoforms are known to have different cellular effects (Zhang 
et al., 2008). For example, altered VEGF121 expression may have contributed to increased 
vascular permeability (Zhang et al., 2008) and subsequently the lack of remodeling in 
Timp1-/- mice. The results of the current study suggest that TIMP1 does not act as an anti-
angiogenic factor, within skeletal muscle, but rather functions as a critical permissive 
factor for flow-induced microvascular remodeling (Figure 5.1A).  
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Figure 5.1: Summary of findings 
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remodeling responses to alterations in flow. 
B) Excess levels of circulating GCs resulted in microvascular rarefaction, reduced skeletal 
muscle blood flow and elicited hypertension. Both Tempol and prazosin treatment had 
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 The rodent model of GC excess was used as a tool to induce deleterious 
microvascular and metabolic effects. This model is pathologically relevant as it mimics 
the phenotype of several human conditions including Cushing’s syndrome, prolonged GC 
treatment, metabolic syndrome and/or type 2 diabetes (Shpilberg et al., 2012).  It was 
hypothesized that CORT treatment would inhibit endothelial mediated shear stress 
signaling and subsequently the angiogenic response to prazosin administration (Chapter 
3). Skeletal muscle microvascular rarefaction was elicited through reduced Ang-1 levels 
and not significant blunting of VEGF expression or increased TSP-1 levels.  Concurrent 
prazosin treatment abrogated rarefaction likely due to the maintenance of MAPK, NO 
and VEGF responsiveness to shear stress; however, in agreement with my hypothesis no 
angiogenic or arteriogenic response occurred. The present study demonstrates that the 
inhibition of α1-adrenergic receptors can prevent CORT-induced capillary rarefaction 
(Figure 5.1B), which could in turn have important benefits for overall skeletal muscle 
health and function and possibly ameliorate the animals’ metabolic profile.  
Based on our previous findings (Chapter 3), we continued using the rodent model 
of GC excess to examine the systemic influences of CORT (Chapter 4). This project was 
embarked upon to test the hypothesis that GC-mediated hypertension and capillary 
rarefaction would be prevented by concurrent treatment with the ROS scavenger Tempol.  
CORT-treatment elicited a significant increase in oxidative stress due in part to a 
reduction in ROS buffering and increased endothelial NADPH-oxidase levels. 
Furthermore, eNOS mRNA was significantly reduced, ET-1 mRNA was significantly 
elevated and relative EDL flow was significant reduced. The current study compared the 
structural and functional effects of Tempol to those seen with prazosin treatment. While 
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both drugs abrogated GC-mediated oxidative stress and hypertension, data from the 
current study suggests that α1-adrenergic receptor inhibition is more beneficial than 
superoxide scavenging alone. Prazosin, but not Tempol, prevented capillary rarefaction 
thereby allowing animals co-treated with prazosin to maintain a reduction in systolic 
blood pressure upon drug cessation. Furthermore, prazosin treated animals saw an earlier 
(day 4 compared to day 7) reduction in systolic blood pressure than Tempol treated 
animals. These findings highlight the important role for adrenergic control of muscle 
flow and oxidative stress in the prevention of the deleterious effects of GC excess (Figure 
5.1B).  
The findings from the abovementioned models (Timp1-/- and GC excess) highlight 
the intricacy of the microenvironment and the importance of proper communication 
between its various components. These studies demonstrate that although one or more 
cell types may be impacted by a given manipulation/situation, the microenvironment has 
tremendous plasticity, redundancy and resilience. These qualities enable the 
microenvironment to function, less than optimally, under pathological conditions.  
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5.2: Study limitations  
There are a several limitations to the studies presented in this dissertation which 
should be mentioned. The first study (chapter 2) was carried out in mice, while later 
studies were performed on rats (Chapter 3, 4 & Appendix A). This was due to the ability 
to genetically manipulate TIMP1 levels in mice that is currently not possible in rats. 
Originally, I had proposed to generate a model of PAD in CORT-treated rats, in order to 
examine ischemia induced remodeling under pathological conditions; however, this 
model proved unviable due to complications in the animals’ post surgery recovery 
(Appendix A). 
I had hypothesized that an increase in C:F would occur only within Timp1-/- mice; 
however, no angiogenic response was seen in Timp1-/- or WT mice. The lack of an 
angiogenic response within Timp1-/- mice demonstrates no excessive increase in MMP-
driven vascular remodeling. The lack of angiogenesis within WT mice may have been 
due to the inhibitory effects of FoxO proteins (Milkiewicz et al., 2011) or it had not yet 
developed. A previous report using a similar model reported an angiogenic response 35 
days post unilateral iliac artery ligation (Milkiewicz et al., 2006).  
For the CORT experiments (Chapters 3 & 4), male rats aged 8 to 9 weeks were 
used. At this age, rats are considered young and are still in a steady growth phase. As a 
healthy rat grows and develops, it stands to reason that skeletal muscle microvascular 
content will increase as well. However, it is possible that within CORT-treated young 
rats, normal capillary growth is blunted thus contributing to the lower C:F values 
reported. This issue could be addressed in future experiments by repeating the 
experimental design in adult age (7 to 8 month old) male Sprague Dawley rats. 
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In Chapter 4 hind-limb blood flow was assessed via a microsphere infusion 
protocol adapted from Deveci & Egginton (1999). An important limitation of the protocol 
I used is that unlike previous investigators, no arterial canulation was used to ensure 
direct microsphere injection or reference sample collection (Deveci and Egginton, 1999; 
Milkiewicz et al., 2006). Furthermore, brain blood flow was used to standardize limb 
blood flow, because brain blood flow should remain relatively constant (Paulson et al., 
1989; Cipolla, 2009). However, previous reports have suggested that GCs can potentially 
affect cerebral blood flow (de Quervain et al., 2003). Care must be taken while 
interpreting the results of the current study as the animals were sedated at the time of 
flow determination, which in itself will reduce blood flow (Raisis, 2005). Furthermore, 
hind-limb basal blood flow can be very low, therefore it may be prudent to examine 
differences in hind-limb blood flow in response to a flow stimulus such as muscle 
contraction (Deveci and Egginton, 1999).  
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5.3: Future directions 
Based on the results obtained from the current experiments, several important 
avenues are of interest for future examination. Within Timp1-/- mice it would be beneficial 
to assess the expression of various VEGF-A isoforms, specifically VEGF165 and 
VEGF121. It is possible that Timp1-/- mice have augmented MMP9 activity; the current 
study (Chapter 2) did not specifically measure MMP9 activity, only overall (MMP1-14) 
MMP-activity. If Timp1-/- mice have excessive MMP9 activity this could result in 
excessive cleavage of VEGF165/185 (Hawinkels et al., 2008), thus allowing VEGF to 
diffuse away from the endothelium where VEGF typically exerts effects. 
Within Chapter 3, I noted a significant increase in VEGF-A mRNA and protein 
expression after 14 days of concurrent prazosin and CORT treatment and maintenance of 
endothelial shear responsiveness. In healthy rats, augmented VEGF-A expression is seen 
prior to an increase in C:F (Milkiewicz et al., 2007). Therefore, future experiments could 
examine if an angiogenic response could be seen in CORT-prazosin animals if the 
experimental conditions were maintained for longer than 2 weeks. As well, it would be 
interesting to examine the health and functionality of the microvascular 
microenvironment in other disease models where skeletal muscle microvascular content 
is reduced, such as type-1 diabetes (Kivelä et al., 2006). 
In Chapter 4, Tempol and prazosin were removed on day 15, 18 hours prior to the 
final systolic blood pressure recording in order to uncover potential structural and/or 
functional similarities/differences between these two drugs. However, this prevented 
assessments of Tempol and/or prazosin induced alterations/ameliorations in relative EDL 
flow.  Future experiments would benefit from determining relative skeletal muscle blood 
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flow within CORT-Tempol and CORT-prazosin groups, while the drug is still being 
administered. This could help to uncover similarities/differences between prazosin and 
Tempol treatment and how these responses differ from control animals.   
Previous investigations have reported an increased prevalence of PAD in patients 
with type-2 diabetes (Ziegler et al., 2010). Therefore, it would be useful to find a model 
of type-2 diabetes in which it is viability to examine PAD. Animal models of type 2 
diabetes such as the ob/ob mouse or the ZDF rat are good candidates. These animal 
models have augmented GC levels (Alberts et al., 2005; Campbell et al., 2010), but not to 
the same extent as the levels reported in the current study. Therefore, either of these 
alternate animal models may be a more suitable model within which to examine PAD. 
This study used pathophysiological levels of CORT, i.e. GC levels were significantly 
greater than those seen in diabetic patients or those on exogenous GC treatment (Alberts 
et al., 2005; Campbell et al., 2010). It would therefore be beneficial to assess lower doses 
of GC, more within the ‘typical’ elevated range and determine the effects on the 
microvasculature and overall cardiovascular health.   
Lastly, as discussed in Appendix B, further experimentation is warranted to refine 
our in vitro assessments of endothelial cell specific alterations to changes in shear stress. 
More specifically, more work is required on endothelial responses to sustained reductions 
in flow. In line with the finings of Appendix B, with elevated blood flow, it would be 
ideal to compare low shear stress (~1-2 dynes/cm2) to normal capillary shear stress (5 
dynes/cm2).  
In summary, the data presented in the current dissertation provide novel 
information regarding the plasticity, resilience and adaptability of the skeletal muscle 
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microvascular microenvironment. My dissertation highlights the importance for balance 
within the microenvironment between growth factors and inhibitors for ‘normal’ 
microvascular development and remodeling. As well, my dissertation points to the 
interconnectivity between skeletal muscle microvascular health and overall 
cardiovascular health.  
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Appendix A: 
The effect of high fat diet on CORT-induced microcirculatory phenotype 
 
Introduction: 
 Glucocorticoids (GC) are steroid hormones known to be elevated in type-2 
diabetes and Cushing’s syndrome (Lansang and Hustak, 2011; Beaudry and Riddell, 
2012). The addition of a high fat diet (HF) to rats treated with corticosterone (CORT) 
more accurately represents the human population with type 2 diabetes and/or metabolic 
syndrome (Shpilberg et al., 2012). Furthermore, the additional of a HF diet exacerbates 
the negative effects of GC excess alone (Shpilberg et al., 2012). 
 Augmented GC levels results in hypertension (Whitworth et al., 2000; Jude et al., 
2010), microvascular rarefaction (Shikatani et al., 2012) and increased risk of developing 
peripheral artery disease (PAD) (Ziegler et al., 2010). PAD is the occlusion of a major 
conduit artery, typically those of lower extremity, which limits oxygen and nutrient 
supply to distal tissues. PAD is commonly studied via femoral or iliac artery ligation of 
small mammals (Lotfi et al., 2013; Krishna et al., 2016). Blood flow recovery depends on 
vascular remodeling, arteriogenesis and/or angiogenesis, within the affected limb (Lotfi 
et al., 2013). Asides from the known anti-hypertensive effects of prazosin (Desiniotis and 
Kyprianou, 2011), it can be used as a tool to study endothelial shear stress 
responsiveness.   
The current study set out to assess the usefulness of the CORT-HF model as a 
model for PAD with concurrent diabetes. We wanted to determine if a) this model is 
viable for testing the influence of hind limb ischemia and b) to examine the effectiveness 
of prazosin in ameliorating the vascular complications seen within this model. It was 
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hypothesized that recovery from femoral artery (FA) ligation would be severely impaired 
and hypertension would develop in CORT-treated animals and this would be improved 
with concurrent prazosin treatment.  
Material and Methods:  
All animal experiments were approved by York University Animal Care Committee and 
conducted in accordance with the Canadian Council for Animal Care Guidelines.  
Animal Protocol 
Male Sprague Dawley rats (N=13; initial weight 200 to 250g) were purchased from 
Charles River Laboratories (Montreal, QC, Canada). For further description see methods 
section chapter 3. 
In the current study all animals were fed a high fat rodent chow diet (5.1kcal/g food) ad 
libitum. Animals were implanted on day negative seven with either wax (control) or 
CORT pellets. 1 week post pellet implantation animals underwent unilateral FA ligation, 
the contralateral limb acting as the control (D0). Subsequently, rodents recovered in 
individual cages and were given ampicillin (20mg/kg body weight) or ampicillin and 
prazosin for the next 2 weeks; see Figure A.1 for full study design. 
Femoral Artery Ligation and hind limb blood flow assessment  
For further detail see methods section chapter 2.  
Briefly, flow assessments were made prior to surgery (Pre), immediately post-surgery 
(D0) and on days 4, 7 and 14 (D4, D7, D14) post-surgery, via laser Doppler imager 
(PeriMed, Stockholm, Sweden). On day 14 post surgery, FA blood flow distal to the 
ligation site and collateral reintegration was assessed using needle laser Doppler probe 
(mooreVMS-LDF2 laser Doppler monitor, Moor Instruments, Delaware USA).   
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Blood Glucose Assessment 
Blood glucose was assessed after on D0, 7 and 14 via hand held glucometer (Contour 
blood glucose meter, Bayer, Toronto, ON). 
Blood Pressure Assessment 
Systolic blood pressure was assessed on D0, 4, 7, and 14. See methods section chapter 4 
for more information.  
Tissue Isolation and Muscle Histology  
See chapter 3 for complete details.  
At the end point, hind-limb skeletal muscles were excised, weighed and subsequently 
snap frozen in liquid nitrogen cooled isopentane.  
Statistical analysis 
Results were expressed as mean + SEM.  
Results:  
 The current study started with 13 animals, with an n of 3 to 4 per group. However, 
due to poor wound healing post FA ligation, a subset of animals (n=5) needed to be 
euthanized early (on day 13 post pellet implantation). Therefore, there were not enough 
animals left to run statistical analysis.  
Systemic effects of sustained elevations in CORT 
There was a trend for a CORT mediated reduction in body weight and relative 
skeletal muscle mass of the TA and EDL, but not the slow twitch soleus (Table A.1). 
Additionally, there is a trend towards greater caloric consumption within the CORT-
animals as compared to control animals. All of the above mentioned morphological 
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measurements were unaffected by prazosin co-treatment. Blood glucose was assessed 
after 2 weeks of concurrent prazosin treatment, and was shown to be lower in CORT-
prazosin animals as compared to CORT-water group. The same trend was seen after one 
week of concurrent prazosin treatment (data not shown).  
Glucocorticoid mediated capillary rarefaction was not abrogated by prazosin treatment 
 As expected CORT-treatment induced capillary rarefaction; however, there was 
no evidence of prevention due to prazosin administration. As well, within control 
animals, no angiogenesis was noted in response to prazosin treatment (Figure A.2A & B). 
Ligation did not appear to alter C:F within any group. C:F was significantly higher in 
control animals fed a HF diet compared to those on a standard chow diet (Figure A.2C & 
D).  
Glucocorticoid mediated cardiovascular and microvascular complications  
 Systolic blood pressure was elevated with CORT-treatment (Figure A.3A). 
Prazosin lowered systolic blood pressure in CORT treated animals, while eliciting only a 
minor reduction in control animals (Figure A.3A).  
 FA ligation reduced relative hind-limb blood flow to approximately 45% 
compared to pre-ligation levels; furthermore, there were no discernable differences in 
flow recovery between groups (Figure A.3B). Needle Doppler assessments of FA flow 
showed a trend for increased flow in the control-prazosin group compared to water group. 
As well, femoral artery blood flow was lower with CORT-treatment, compared to control 
animals, regardless of prazosin being present (Figure A.3C).  
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Table A.1: Animal characteristics after 3 weeks of CORT treatment with or without 2 
weeks of prazosin co-treatment 
 
 Control Water 
(n=2) 
Control 
Prazosin 
(n=2) 
CORT Water 
(n=3) 
CORT 
Prazosin 
(n=1) 
Body weight (g) 419.1 410±20.75 272.4±14.9 292.9 
Blood Glucose 
(mmol/L) 6.1 5.6±0.5 21.6±1.3 5.9 
TA relative weight 
(g/kg BW) 1.64 1.72±0.02 1.35±0.15 1.43 
EDL relative 
weight (g/kg BW) 0.46 0.49±0.001 0.39 ±0.05 0.422 
Soleus relative 
weight (g/kg BW) 0.43±0.005 0.44 ±0.01 0.47±0.007 0.551 
Heart relative 
weight (G/kg BW) 1.28±0.17 1.13±0.1 0.90±0.05 0.90 
Food consumption 
(kcal/g BW) 0.275±0.02 0.26±0.03 0.35±0.03 0.36 
Average water 
consumption 
(ml/day) 
40.88±15.5 34.04±11.1 58.2±13.1 40.56 
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Discussion: 
The current study utilized the addition of hind-limb ischemia to the CORT-HF 
model to study intermittent claudication within the context of type-2 diabetes. However, 
the immunosuppressive effects of Cort resulted in poor wound healing making this an 
unsuitable model. 
In line with results seen in chapter 3, CORT-HF treatment elicited skeletal muscle 
capillary rarefaction. However, this was not prevented with concurrent prazosin 
treatment. Unexpectedly, the current study noted no angiogenic effects of prazosin within 
control animals, which may be due to the concurrent consumption of a high-fat diet. 
Previous research has reported that a high fat diet will increase C:F (Silvennoinen et al., 
2013), which is in line with findings from the current study. In the current study, control-
chow animals (used in chapter 3) were pooled with current and previous control-HF 
animals; this data revealed that short term HF-diet significantly increased C:F. Therefore 
a basal increase in C:F, due to the HF-diet, may have prevented prazosin from exerting 
further angiogenic effects.  
As expected (Mondo et al., 2009; Bachhav et al., 2011; Hattori et al., 2013), 
CORT-treatment elicited hypertension, which was prevented with concurrent prazosin 
treatment. Therefore the vasodilatory benefits of prazosin, while insufficient to prevent 
rarefaction could prevent CORT-induced hypertension. Direct assessment of FA flow, 
distal to the ligation site, revealed a possible benefit of prazosin treatment within control 
animals. Interestingly, FA flow was noticeably reduced within CORT-treated animals 
regardless of prazosin co-treatment, which is suggestive of impaired arteriogenesis. This 
is in line with a recent report that dexamethasone-treatment impaired arteriogenesis in a 
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mouse model of hind limb ischemia (Troidl et al., 2013). Unexpectedly the current study 
noted an apparent abolishment of CORT-mediated hyperglycemia with concurrent 
prazosin treatment, which was not seen previously in CORT-chow animals (Dunford et 
al., 2016). Therefore, care should be taken when drawing conclusions, as they may 
simply be sample issues or a result of being a fed assessment.  
Although the current project proved nonviable it provided valuable information 
that aided in chapter 4’s study design.   
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Appendix B: 
Effect of basal versus elevated shear stress on endothelial cell shear responsiveness 
Introduction: 
The effects of alterations in shear stress, the frictional force exerted by blood as it 
flows past the vessel wall, is commonly investigated in vitro via parallel flow chamber. 
Endothelial cells are plated on a cover slip placed on the bottom of a rectangular channel 
with a uniform height along the length of the flow path. The flow of media is generated 
using a mechanical pump at the desired shear stress intensity (Ives et al., 1986; Chien, 
2007).  After exposing the endothelial cells to a shear stimulus for a set period of time the 
cells can be lysed and subsequently analyzed for changes in protein and/or mRNA 
expression.  
An in vitro shear stress intensity of 15 dynes/cm2 mimics the intensity seen in vivo 
due to prazosin administration (Milkiewicz et al., 2001). Traditionally, assessments of  
“elevated” shear stress are made relative to static control. However within a healthy 
capillary bed, basal shear stress is not 0 dynes/cm2 but rather 5 dynes/cm2 (Hudlicka et 
al., 2006). Therefore, the current study set out to examine differences in the expression of 
two key angiogenic factors, VEGF-A and MMP2, under static, 5 and 15 dynes/cm2 of 
shear stress. It was hypothesized that comparing “elevated” to “normal” shear stress will 
provide the most accurate representation of alterations in endothelial cell shear 
responsiveness. 
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Materials & Methods: 
Cell culture and shear stress stimulation 
Skeletal muscle microvascular endothelial cells were isolated from extensor 
digitorum longus (EDL) muscle of male Sprague Dawley rats as described previously 
(Han et al., 2003). Shear stress experiments were conducted as previously described 
(Milkiewicz et al., 2006). Briefly, cells were subjected to 5 or 15 dynes/cm2 shear stress 
for 24 hours using a parallel plate flow system (Bioptechs), or remained under static 
conditions, as described in Chapter 2 and 3.  
RNA extraction and Real Time qPCR 
RNA was isolated from endothelial cells using Cell-to-cDNA lysis buffer (Ambion, 
AM8723) as per the manufacturer’s instructions. RNA was reverse transcribed using 
MMLV reverse transcriptase (New England Biolabs, Whitby ON Canada). cDNA were 
analyzed by Taqman qPCR using qPCR mastermix (#4444963; Invitrogen Canada) and 
Taqman probes for mouse VEGF (Mm00437306), MMP2 (Mm00439498) or GAPDH 
(Mm99999915). 
Statistical Analysis 
Results were expressed as mean ± SEM and analyzed by one-way ANOVA with 
subsequent Bonferroni post hoc tests where appropriate (Prism4; Graphpad software Inc; 
La Jolla, CA, USA). P < 0.05 was considered statistically significant.  
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Results: 
5 dynes/cm2 of shear stress did not significantly alter VEGF-A mRNA compared to static 
control. 15 dynes/cm2 elicited a significant increase in VEGF-A mRNA compared to both 
static (*** P<0.001), and 5 dynes/cm2 (## P<0.01) (Figure B.1A).  
Both 5 and 15 dynes/cm2 of shear stress significantly reduced MMP2 mRNA (*,** 
P<0.05 and 0.01 respectively) as compared to static controls. No significant differences 
in MMP2 mRNA expression between 5 and 15 dynes/cm2 of shear stress were noted 
(Figure B.1B). 
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Discussion: 
The results from the current study demonstrate that comparing “elevated” (~15 
dynes/cm2) to “normal” (~5 dynes/cm2) shear stress conditions in vitro may more closely 
mimic in vivo conditions.  The alterations in VEGF-A mRNA to elevated shear stress was 
the same when comparing elevated shear stress to static or normal shear stress conditions. 
However, the expected reduction in MMP2 due to elevated shear stress (Rivilis et al., 
2002) was abolished when comparing elevated shear stress or normal conditions. Thus 
comparing the 15 dynes/cm2 to 5 dynes/cm2 provides different information than 
comparing 15 dynes/cm2 to static controls.  
This study is merely preliminary work; however, these findings suggest that it 
may be ideal to compare alterations in shear stress to normal (5 dynes/cm2) shear stress 
rather than static controls.  Doing so will likely provide a more accurate in vitro model of 
how elevated shear stress is impacting endothelial production of pro or anti-angiogenic 
factors.  More work is needed to evaluate this model in greater detail and analyze 
additional factors that are altered by elevated shear stress.  
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